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ABSTRACT OF DISSERTATION 
THE ROLE OF NEURAL PRECURSOR CELL EXPRESSED DEVELOPMENTALLY 
DOWN-REGULATED PROTEIN 9 IN INHANCED AGGRESSIVENESS OF 
HEXAVALENT CHROMIUM TRANSFORMED BRONCHIAL EPITHELIAL CELLS 
Hexavalent chromium (Cr(VI)) is classified as a confirmed human carcinogen by 
the International Agency for Research and Cancer (IARC) and by the U.S. Environmental 
Protection Agency (EPA). Chronic exposure to (Cr(VI)) causes malignant cell 
transformation in human bronchial epithelial BEAS-2B cells. These Cr(VI)-transformed 
cells exhibit a highly aggressive phenotype including increased migration, invasion, and 
angiogenesis. The Cas family protein neuronal precursor developmentally down regulated 
protein 9 (NEDD9/Cas-L/HEF1) was dramatically overexpressed in Cr(VI)-transformed 
cells compared to normal BEAS-2B cells. Knockdown of NEDD9 by its shRNA reduced 
migration and invasion in vitro measured by migration and invasion assays. shNEDD9 
reduced tumor formation in nude mice injected subcutaneously and metastasis in mice 
injected in the lateral tail vein. NEDD9 is critical for the activation of c-Src kinase (Src) at 
Y416 and overexpression of focal adhesion kinase (FAK). These interactions with NEDD9, 
FAK, and Src indicate that NEDD9 was acting upstream from FAK and Src in Cr(VI)- 
transformed cells. NEDD9 expression or Src activation had downstream effects on 
migration and invasion. Interestingly β-Catenin activity was positively regulated by the 
expression of NEDD9 and the activation of Src. NEDD9 is critical for HIF-1α expression 
which leads to angiogenesis. The NEDD9 mediated angiogenic proteins VEGF, PECAM, 
ANG1, and MMP proteins are overexpressed in Cr(VI)-transformed cells. NEDD9 may 
increase angiogenesis by first mediating the phosphorylation of p38 and then HIF-1α. 
NEDD9 can also bind directly to CREB binding protein (CBP) a critical cofactor for HIF- 
1α transcriptional activity. These results lead us to believe that NEDD9 is a driving force 
in lung cancer aggressiveness by magnifying migration and invasion by facilitating 
FAK/Src binding and activation of Src kinase, by increasing β-Catenin activity and by 
increasing angiogenesis through HIF-1α stabilization and overexpression of downstream 
angiogenic proteins. 
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CHAPTER 1. INTRODUCTION TO ENVIRONMENTAL AND OCCUPATIONAL EXPOSURE TO
HEXAVALENT CHROMIUM AND TUMOR AGGRESSIVENESS 
1.1 Exposure to Heavy Metal 
Heavy metals are ubiquitously present and can be concentrated in areas through 
natural or human forces. Their wide spread uses in many industrial applications have 
caused an increasingly vigilant awareness of the health effects of living near heavy metal 
hot spots. There are a handful of metals that have essential nutritional value for 
biochemical and physiological functions including cobalt (Co), copper (Cu), iron (Fe), 
magnesium (Mg), manganese (Mn) and zinc (Zn) [1]. These elements are found in trace 
quantities of the magnitude of ppb often in various matrices such as soils, dust, and 
plants, or can be found in various oxidized states. These can be received in the diet 
through food or ground water. Heavy metals in large doses can have devastatingly 
negative health effects and some heavy metals should be avoided as much as possible. 
The strongest carcinogenic heavy metals are chromium (Cr), arsenic (As), cadmium (Cd), 
and Nickel (Ni) [2]. 
Hexavalent chromium (Cr(VI)) has an oxidation state of +6. Each year massive 
amounts of hexavalent chromium are produced. For example, in 1985 300 thousand 
pounds of hexavalent chromium was produced [3]. Besides the prolific industrial use of 
hexavalent chromium, it exists in nature as these common conglomerates: ammonium 
dichromate, barium chromate, calcium chromate, chromium trioxide, lead chromate, 
sodium dichromate, strontium chromate, potassium chromate, potassium dichromate, 
sodium chromate and zinc chromate [4]. One major route of exposure for hexavalent 
chromium is through drinking water. Awareness for this exposure has become 
popularized in documentaries and movies such as Erin Brockovich. A second and 
possibly more dangerous matric is aerosolized Cr(VI). Accumulation of Cr(VI) has been 
observed in the lungs of chromate workers, leading to increased incidence and severity of 
lung cancer. 
Several critical epidemiologic studies illustrate the pressing need to address this 
issue. A study was conducted in 1987 illustrating multiple occurrences of lung cancer in 
chromate workers. The average duration of exposure was 24 years, and the primary sites 
were all in the large bronchi. The incidence of lung cancer in these chromate workers was 
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657.9 per 100,000 compared to 13.3 per 100,000 in the total population [5]. The dose 
response for those exposed to occupational chromate was reported by Tsuneta et al. in 
their study published in 1987 [6]. This study showed that increasing doses and longer 
time intervals of exposure were associated with lung cancer. In 1990, a review of many 
cases over decades revealed a dose dependent response with increasing lung cancer. This 
review presents evidence that more soluble chromates are more dangerous. The most 
potent forms were zinc chromate, calcium chromate, and Cr(VI) [7]. 
Trivalent chromium (Cr(III)) has a oxidation state of +3. It is the primary resting 
state that chromium is found in the environment. Trivalent chromium has industrial uses. 
Cr(III) acetate is used in the textile industry for fixing dyes and photography, and Cr(III) 
nitrate is used for catalysis, anti-corrosion, and textiles [8]. Cr(III) is a dietary supplement 
that has uses for blood sugar control in people with prediabetes, type one, and type two 
diabetes [9]. Theoretically Cr(III) is carcinogenic as it can generate DNA adducts causing 
increased mutation. However, in physiological pH conditions Cr(III) cannot enter the cell 
[10]. For this reason not much emphasis has been placed on regulating Cr(III) exposure. 
Hexavalent chromium is used in similar occupational settings as trivalent 
chromium. Cr(VI) is used in the production of metals such as stainless steel to increase 
the hardness, and for resistance to corrosion. Cr(VI) fumes are released during the 
production of these metals and it exists in welding fumes as well. It is used in paints, 
dyes, inks, primers, plating for pigmentation, and anticorrosive agent [11]. The industrial 
applications are most detrimental if Cr(VI) exposure reaches the respiratory system, 
kidney, liver, eyes or skin. Unlike Cr(III), Cr(VI) can enter the cell at physiological pH. 
Once Cr(VI) is inside the cell there is a cascade of effects leading to increased oxidative 
stress, metabolic reprograming, DNA damage and ultimately carcinogenesis. 
The best known carcinogenic heavy metals are Cr, Cd, Ni, and As. These metals 
share some similar mechanisms of action for causing cellular damage and carcinogenesis. 
While they have similarities, each also diverges into its own specialized pathways. 
Arsenic is classified as a group 1 carcinogen by the International Agency for Research on 
Cancer (IARC). Inorganic arsenic in drinking water has been solidly linked to bladder, 
liver, lung, prostate, skin cancer, and other diseases for example, cardiovascular disease, 
diabetes, and hypertension [12]. Much like Arsenic, Nickel is a group 1 carcinogen by 
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IARC standards. Ni(II) is genotoxic, mutagenic, and generates high levels of reactive 
oxygen species (ROS) with many downstream consequences. Nickel is most potent when 
it interacts with other metals in the cell such as Fe(II), Mg(II), Mn(II), Ca(II), and Zn(II) 
either by interacting with them directly, or affecting their metabolic states [13]. Cd, 
similar to the aforementioned heavy metals, is classified as a group 1 carcinogen by 
IARC. Target organs for Cd induced lung, liver, pancreas, and stomach. Most studies of 
Cd identify only a weak connection with mutagenesis. The mechanism then for Cd is 
most likely epigenetic by overexpressing oncogenes, pro-survival genes, inhibiting the 
expression of tumor suppressors, and apoptosis. Hexavalent and trivalent chromium we 
have briefly touched on in the previous paragraphs so next I will move to discuss the 
signaling pathways that these metals mediate. 
One of overlapping effect of all four metals is the ability to generate reactive 
oxygen species (ROS). The mechanism by which each metal generates ROS varies 
between Cr, Cd, Ni, and As. Cr(VI) enters the cells and generates ROS by reducing 
Cr(VI) to Cr(V), Cr(IV), and Cr(III) and back again releasing hydrogen peroxide, 
hydroxyl radicals, singlet oxygen, and superoxide radicals [14]. The reduction of Cr(VI) 
is catalyzed by glutathione, ascorbate, and Fenton. Cd generates ROS and nitric oxide 
radicals using largely the same enzymes, Fenton metals, glutathione, superoxide 
dismutase, and catalase but Cd does not undergo the same reduction and oxidation 
process that Cr(VI) does. Ni and As are processed by the same antioxidants as well 
producing hydrogen peroxide, hydroxyl radicals, singlet oxygen, and superoxide radicals. 
Arsenic behave the most similar to Cr in the reduction and oxidation process releasing 
ROS by reduction of As(V) to As(III). 
There are many mutagenic pathways that can be set into motion by exposure to 
heavy metals. Arsenic can cause DNA damage by blocking p53, ATM, ATR, and other 
important regulators for DNA repair [15]. Chromium can cause harmful DNA damage 
when reduced from Cr(VI) to Cr(III). The result is base modifications, single-stranded 
and double-stranded breaks, Cr-DNA adducts, DNA-Cr-DNA adducts, and protein-Cr- 
DNA adducts [16]. Epigenetic modifications also play a large in metal induced 
carcinogenesis. Affected pathways have downstream effects on DNA methylation, 
chromatin modification, and changes in expression of non-coding RNAs [17]. In addition 
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to these mutagenic and epigenetic effects of heavy metal exposure, many of the major 
pathways in cancer are affected. Cancer signaling pathways including, Wnt/β-Catenin, 
TNF𝛼𝛼, NF𝜅𝜅B, and effects on apoptosis and anoikic resistance, cytoskeletal remodeling, 
and integrin signaling [18]. 
All of these effects of heavy metals make its study both broad and deep. For the 
scope of this dissertation we will now focus on Cr(VI) to more deeply describe how it is 
involved in the carcinogenic process and how it leads to increased tumor aggressiveness. 
1.2 Tumorigenesis 
Figure 1.1 Hexavalent chromium penetrates the plasma 
membrane and increases tumorigenesis. 
The initial stages 
of Cr(VI) induced 
carcinogenesis involve 
several mechanisms. 
Cr(VI) is water-soluble 
compared to the other 
oxidative states and can 
enter the cell by 
various transporters. 
Because of its 
remarkable structural 
similarity to SO42- and 
HPO42- Cr(VI) (CrO42-) 
is ushered through the 
cell membrane via ion 
channels such as the sulfate ion channel and other nonspecific transporters [19, 20]. Most 
of Cr(VI) is reduced to Cr(III) in the cytosol, but a fraction of Cr(VI) reaches the nucleus. 
Cr(III) can also be oxidized back into Cr(VI) by oxidizing agents in the cell. Cr(VI) is 
more highly reactive and it is likely the precursor that gives rise to Cr(III)-DNA adducts 
[21, 22]. DNA damage and adducts can arise when Cr(VI) is reduced by the major 
antioxidant proteins in the cell including glutathione, cysteine, and ascorbate which are 
each highly reactive with Cr(VI), Cr(V), and Cr(IV). The result of these reductions 
occurring within the nucleus leads to single-stranded and double-stranded breaks, alkali- 
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labile sites, DPCs, DNA amino acid cross-links, Cr-DNA adducts, and protein-Cr(III)- 
DNA crosslinking [22]. Once inside the cell, Cr(III) can cause DNA damage by a 
different mechanism by interfering with base-pair stacking. Cr(VI) compounds in the 
lung have been documented to cause both adenine and guanine mutations in p53 [22]. 
The process of reduction from Cr(VI) to Cr(V), Cr(IV), and Cr(III) gives rise to ROS 
with many downstream effects including alterations in cell signaling and cellular 
metabolism [23]. ROS released during this reduction include super-oxide anions, and 
hydrogen peroxide. Further generating of ROS continues to produce hydroxyl radicals, 
singlet oxygen, superoxide, and hydrogen peroxide via Fenton pathways and other 
antioxidant pathways [22]. 
Several major pathways including oxidative phosphorylation are altered in cells 
treated with Cr(VI). Cr(VI)-transformed cells showed a suppression in all five 
mitochondrial complexes involved oxidative phosphorylation. The complexed that 
showed the most changes were complex I, II, and V. Changes in mitochondrial 
complexes led to a reduction of mitochondrial ATP production and non-mitochondrial 
oxygen consumption was increased [24]. Some of the critical enzymes for ATP 
production were altered in Cr(VI)-transformed cells from an RNA sequencing analysis. 
The genes upregulated in these cells included ADP-specific glucokinase (ADPGK), 
enolase 1 (ENO1), hexokinase (HK2), phosphoglycerate kinase (PGK1), 
dihydrolipoamide S-acetyltransferase (DLAT), pyruvate dehydrogenase E1 (PDHA1), 
glucose-6-phosphatase 3 (G6PC3), pyruvate kinase (PKM), aldolase A (ALDOA), and 
phosphofructokinase (PFKM) [23]. 
Hexavalent chromium interacts with a subset of phosphatidylinositol 3-kinase 
binding proteins which can mediate signal transduction. The peroxide generation 
capability of Cr(VI) is a contributor in the upregulation of these pathways. One major 
result of these alterations is a change in MAP kinase which can affect growth and 
differentiation. This activation results in ERK1 and ERK2 activity and the positive 
modulation of Ras and downstream Raf-1 phosphorylation [25]. BEAS-2B cells have 
shown activation of EGFR signaling signified by a marked increase of p-EGFR(1068) 
when treated with Cr(VI) at 0.25 μM. The EGFR signaling was increased each month 
that the cells were treated with a peak expression around 4 months. Hydrogen peroxide 
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elevation induced NOX1 activation that was required for the phosphorylation of EGFR. 
Further signaling pathways were initiated including c-Src/ERK, p38/AKT, and MAPK 
[26]. 
Exposure of BEAS-2B cells to Cr(VI) caused apoptosis resistance by decreasing 
levels of C-PARP and Bax while elevating anti-apoptotic Bcl-2 and Bcl-xL. The 
inhibition of EGFR resumed apoptosis as normal in these cells by increasing Bax and 
reducing Bcl-2 expression [26]. It was reported that Cr(VI) increases apoptosis resistance 
by inhibiting the tumor suppressor p53, then PUMA/NOXA, resulting in Bcl-2 and Bax 
elevation [27]. However, in lung fibroblasts Cr(VI) was observed to have an opposite 
effect, transiently activating p53 causing upregulation of pro-apoptotic Bcl-xS and 
downregulation of anti-apoptotic Bcl-w and Bcl-xL [28]. 
Cr(VI) can induce autophagy which in some cells can lead to apoptosis, but in 
A549 cells and BEAS-2B cells, Cr(VI) induced autophagy promoted cell growth and 
proliferation [29, 30]. Endoplasmic reticulum (ER) stress occurred post Cr(VI) exposure 
by the upregulation of GRP78, p-PERK, and ATF6. This ER stress resulted in an increase 
in autophagy to reduce the burden of unfolded proteins. This is thought to be one of the 
mechanisms that Cr(VI) can reduce cell death in cancer cells [29]. ROS production 
generated from Cr(VI) exposure can induce mitochondrial dependent apoptosis. The 
activation of autophagy on Cr(VI)-transformed cells may be a critical component for 
repairing mitochondrial function and preventing cell damage and apoptosis [31]. 
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1.3 Aggressiveness 
A study found that Cr(VI)-transformed BEAS-2B cells had 409 differently 
expressed genes compared with normal BEAS-2B cells. Out of these genes, 12 critical 
Focal adhesion genes were altered [32]. The major components of the desmosome 
complex DSC2, DSC3, and Prep were increased at least 5 fold in Cr(VI)-transformed 
cells. Cadherins involved in adherens junctions and tight junctions were upregulated at 
least 2 fold. L1CAM was increased at least 4 fold. These indicate that Cr(VI) exposure 
leads to significant changes in focal adhesion [32]. 
Out of the 409 differently expressed genes identified in Cr(VI)-transformed cells, 
significant downregulation was found in all cytoskeletal targets influencing cytoskeletal 
structure and cell junctions [32]. Matrix integrity was altered by downregulation of 
collagen α2. Cadherins associated with cell differentiation were downregulated. Integrin 
β4, a major factor in cell-matrix and cell-cell adhesion was downregulated. Zinc binding 
protein was accumulated in a phosphorylated form at the cell surface. This accumulation 
plays a role in generating focal adhesion sites and cell signal transduction. Lastly, 
differences were found upon examining urokinase type plasminogen activator (UPAR) 
and the CI-B18 gene. These data point to cell transformation and unusual adhesion states 
in Cr(VI)-transformed cells [33]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Two critical cellular adhesions 
Focal adhesion kinase (FAK) 
and NEDD9 interact with  a 
myriad adhesion molecules to 
increase cellular invasion and 
metastasis [34][35, 36]. FAK is a 
non-receptor tyrosine kinase that 
regulates cellular adhesion at the 
basal lamina and increases 
motility, proliferation, and cell 
survival in cancer [37]. FAK is 
initially autophosphorylated at 
Y397 which allows for further 
activation and the formation of 
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the FAK/Src complex [37]. c-Src (Src) is a non-receptor tyrosine kinase belonging to a 
larger family of homologs with the collective name Src family kinase (SFK). Formation 
of the FAK/Src complex increases Src activation signified by phosphorylation at Y416 
[38, 39]. Active Src kinase increases invasion and metastasis by activating multiple 
downstream targets and induces signal transducers for proliferation, cell growth, cell 
survival, differentiation, cell shape, motility, migration and angiogenesis [40]. NEDD9 is 
known to interact with FAK and Src, however; the exact mechanism of this critical 
interaction has been disputed. It has been reported that NEDD9 was the downstream of 
FAK/Src complex and its upregulation was dependent on Src activation [41] or FAK 
activation [42]. It has also been reported that NEDD9 was an upstream event of FAK, Src 
and other effectors [36, 43, 44]. Thus, some researchers suggest a positive feedback loop 
between NEDD9 and FAK or Src [34]. 
The formation of lamellipodia relies on FAK and the recruitment of Src. 
Lamellipodium at the leading edge respond to migratory signaling and are essential for 
migration and invasion. Migrating cells are polarized with a broad leading edge and a 
narrow trailing edge [45]. FAK and Src may be involved in migration by contributing to 
turnover at the front end of a cell [46-48]. Cells with forced deficiency of focal adhesion 
proteins were unable to release their trailing edges and lacked the ability to recruit further 
migration signaling molecules such as Crk and paxillin and a complex for guanine 
exchange with Rac in the leading edge [49]. 
The second essential adhesion site for epithelial are the adherens junctions. Figure 
2 shows that while FAK/Src interactions govern the adhesion and signaling with the basal 
laminal extracellular matrix proteins, the adherens junctions govern cell to cell adhesion 
and signaling [50]. Adherens junctions are formed by E-Cadherin proteins protruding out 
of the cell and interacting with the E-Cadherin from neighboring cells. E-Cadherin is 
associated with β-Catenin at these sites as part of normal cellular adhesion [50, 51]. 
When E-Cadherin is lost or cleaved the adherens junctions are undermined and adhesion 
is altered [52, 53]. 
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Figure 1.3 β-Catenin disassociates from the destruction complex in many cancer- 
like conditions 
Cleaved E-cadherin can function either intercellularly or intracellularly as a 
signaling molecule. E-cadherin is cleaved in the intercellular space by MMPs and can 
feedback as a ligand with membrane bound E-cadherin. It can also be cleaved 
intracellularly by γ-secretase [53]. The intracellular fragments have not been well studied 
and their mechanism of action has not been well defined. When cleaved E-Cadherin 
fragments are found inside the cell they have been associated with Wnt signaling and the 
disassembly of adherens junctions [53]. It is also likely that leaved E-cadherin interacts 
with β-Catenin and may cause pooling in the cytosol. 
 
 
Figure 1.4 E-cadherin is lost or cleaved in many cancer-like conditions 
 
 
Cas family proteins including NEDD9 are necessary for FAK/Src dependent 
angiogenesis [54]. This process releases or activates several key molecules including 
RhoA, Rock, Nck2, and Cdc42 that are required for sprouting new vasculature [55-58]. 
In addition, NEDD9 was linked with the major angiogenic indictable factor HIF-1α 
[59]. These signaling factors had downstream effects on MMP secretion and membrane 
protein recycling as a part of tumor cell angiogenesis and invasion of endothelial cells. A 
tumor can only grow to be about 1-2mm3 before the center of the tumor begins to 
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undergo necrosis [60]. At this point angiogenesis becomes necessary for tumor growth. 
Without angiogenesis the metabolic and nutritional demands increase and oxygen levels 
become damagingly low. 
HIF-1α is the major inducible factor that can respond rapidly to the variable oxygen 
levels in the cell. Under normoxia HIF-1α undergoes hydroxylation by the PHD family of 
proteins. HIF-1α is then associated with VHL and ubiquitinated. This keeps HIF-1α 
levels controlled under normoxia through proteasomal degradation. In hypoxic 
conditions, PHD1 and PHD3 are degraded which allows for free HIF-1α in the cell. HIF- 
1α forms a dimer with HIF-1β and is translocated to the nucleus. CREB-Binding Protein 
(CBP) and p300 are cofactors that increase association with the DNA and the HIF 
complex. Angiogenic and erythropoietic genes are transcribed at the hypoxia response 
element (HRE) including VEGF and about 60 other genes. 
 
Figure 1.5 HIF-1α activity in normoxic and hypoxic conditions 
 
 
Vascular endothelial growth factor (VEGF) is one of the most important 
downstream targets of HIF-1α. It is a secreted protein that binds to the VEGF-R to 
activate several signaling pathways. VEGF can activate Ras/MAPK resulting in cell 
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proliferation. The Ras/Raf cascade is initiated by VEGF-R through the recruitment of 
Src. The downstream MAP kinases ERK1/ERK2 are activated [61]. VEGF-R activates 
FAK/paxillin to promote cytoskeletal rearrangement and migration. VEGF promotes 
FAK activation and localization to cell-cell junctions. FAK binds to the vascular 
endothelial cadherin (VE-Cadherin) and induces active β-Catenin. This facilitates VE- 
Cadherin and β-Catenin dissociation as a critical part of cytoskeletal rearrangement [62]. 
Small GTPase RhoA is also an important downstream target of VEGF. The RhoA/ROCK 
activation is necessary in aiding the formation of new vasculature and vascular 
 
Figure 1.6 VEGF signaling on endothelial and other cell types 
 
 
permeability. VEGF also has extended cellular effects on motility, proliferation, and 
survival [63]. 
VEGF is regulated not only by HIF-1α but also by p38 which is a MAPK family 
protein. p38 associates with scaffolding proteins in the Cas family and here we propose 
the importance of its interaction with NEDD9. The role of p38 as it relates to 
angiogenesis is that p38 can shift the signaling implications of VEGF to induce 
angiogenesis or vascular permeability [64]. The activation of p38 causes activation of 
MAP kinases protein kinase 2/3 and the polymerization of F-actin. These effects on 
microfilaments induce cytoskeletal rearrangement as a critical part of cell migration and 
angiogenesis [65, 66]. 
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This dissertation will examine the role of NEDD9 in signaling pathways of 
migration, invasion, and angiogenesis including FAK/Src, E-Cadherin/ β-Catenin, HIF- 
1α/VEGF, and MAP kinase p38. We have found significant data to support that NEDD9 
is critical in these pathways and their downstream effects on cancer aggressiveness. 
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CHAPTER 2. UPREGULATION OF NEDD9 PROMOTES MIGRATION AND INVASION
THROUGH FAK/SRC AND Β-CATENIN/E-CADHERIN PATHWAYS IN CHROMIUM(VI)- 
TRANSFORMED BRONCHIAL EPITHELIAL CELLS. 
2.1 Abstract 
Chronic exposure to hexavalent chromium (Cr(VI)) causes malignant cell 
transformation in human bronchial epithelial BEAS-2B cells. These Cr(VI)-transformed 
cells exhibit a highly aggressive phenotype including increased migration and invasion. 
The Cas family protein neuronal precursor developmentally down regulated protein 9 
(NEDD9/Cas-L/HEF1) is dramatically overexpressed in Cr(VI)-transformed cells 
compared to normal BEAS-2B cells. Knockdown of NEDD9 by its shRNA reduced 
migration, invasion in vitro and in vivo. NEDD9 is critical for FAK expression and the 
activation of Src kinase at Y416 through direct binding. These interactions with NEDD9, 
FAK, and Src indicate that NEDD9 is acting upstream from FAK and Src in Cr(VI)- 
transformed cells. Src activation had downstream effects on migration and invasion. 
Interestingly β-Catenin activity was positively regulated by the expression of NEDD9 
and the activation of Src, but the canonical EMT Wnt targets Snail, Slug, and Twist were 
not elevated. These results lead us to believe that NEDD9 is a driving force in migration 
and invasion by facilitating FAK/Src binding and activation of Src kinase. 
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2.2 Introduction 
Hexavalent chromium (Cr(VI)) compounds are confirmed human carcinogens by 
the International Agency for Research on Cancer (IARC) and U.S. Environmental 
Protection Agency (EPA) [67]. Chronic exposure of human bronchial epithelial (BEAS- 
2B) cells to low dose of Cr(VI) induced malignant cell transformation. Our previous studies 
have demonstrated that those Cr(VI)-transformed cells exhibit reduced capacity of 
generating reactive oxygen species (ROS) and increased angiogenesis, contributing to 
tumorigenesis of Cr(VI)-transformed cells [26, 68, 69]. However, the mechanism of 
aggressiveness of those Cr(VI)-transformed cells is still unknown. This study investigated 
the underlying mechanism of migration, invasion, and metastasis of Cr(VI)-transformed 
cells. 
Neural precursor cell expressed developmentally down-regulated protein 9 
(NEDD9) is a scaffolding protein that belongs to the CAS family of adaptor proteins [54, 
70]. Growing evidence indicated that NEDD9 is upregulated in cancer and may be linked 
with other diseases as well [6, 36, 71-79]. Elevated NEDD9 expression has been associated 
with cancer progression in multiple cancer types including to lung [71], breast [72], 
melanoma [73, 74], colon [75], liver [36], pancreatic [76, 77], prostate [78], and kidney 
[79]. NEDD9 facilitates the assembly of many complexes involved in oncogenic signaling. 
These oncogenic signaling pathways are vitally important in cancer progression. Some of 
the most important pathways mediated by NEDD9 include Src oncogenic pathways, focal 
adhesion, cell cycle checkpoints, lamellipodia formation, and immune control [80]. 
Inhibition of NEDD9 expression causes a dramatic decrease in tumor size and number and 
reduces aggressiveness [79-81]. 
There is evidence that NEDD9 interacts with key focal adhesion molecules to 
increase cellular invasion and metastasis [34][35, 36]. Focal adhesion kinase (FAK) is a 
non-receptor tyrosine kinase that regulates cellular adhesion at the basal lamina and 
increases motility, proliferation, and cell survival in cancer [37]. FAK is initially 
phosphorylated at Y397 which allows for further activation and the FAK/Src complex is 
born. [37]. Src is a non-receptor tyrosine kinase belonging to a larger family of homologs 
with the collective name Src family kinase (SFK). Formation of the FAK/Src complex 
increases Src activation commonly signified by phosphorylation at Y416 [38, 39]. Active 
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Src kinase increases invasion and metastasis by activating multiple downstream targets 
including signal transducers for proliferation, cell growth, cell survival, differentiation, cell 
shape, motility, migration and angiogenesis [40]. 
NEDD9 is known to interact with FAK and Src, however; the exact mechanism of 
this critical interaction has been disputed. It has been reported that NEDD9 was the 
downstream of FAK/Src complex and its upregulation was dependent on Src activation 
[41] or FAK activation [42]. It has also been reported that NEDD9 was an upstream event 
of FAK, Src and other effectors [36, 43, 44]. Thus, some researchers suggest a positive 
feedback loop between NEDD9 and FAK or Src [34]. 
Additionally, recent studies have shown linkages between NEDD9 and β-Catenin 
or E-cadherin may also be a major role in NEDD9-mediated aggressiveness [44, 75]. This 
would indicate that NEDD9 is vital for both basal laminal adhesion and cell adhesion 
junctions, placing NEDD9 as a critical focal point in cancer cell survival and 
aggressiveness. However, the mechanism by which these pathways converge is still 
unknown. Canonically, phosphorylated β-Catenin regularly destroyed by the destruction 
complex adenomatous polyposis coli (APC), Axin, casein kinase 1 (CK1), protein 
phosphatase 2A (PP2A), Ser/Thr kinases glycogen synthase kinase 3β (GSK-3β), and β- 
transducin repeats-containing proteins (β-TrCP) which ubiquitinates β-Catenin for 
proteasomal degradation [83]. In many cancers when Wnt signaling is activated, non- 
phosphorylated β-Catenin pools in the cytosol and nucleus to upregulate genes associated 
with TCF/LEF enhancing cell survival, and at times causing a stem-like phenotypes. Active 
GSK-3β is a critical kinase in the β-Catenin destruction complex that phosphorylates β- 
Catenin in preparation for ubiquitination via the E3 ubiquitin ligase β-TrCP. Reduction of 
GSK-3β can lead to overexpression and pooling of β-Catenin [84, 85]. 
Reduced E-Cadherin is a recognized marker of cancer progression. E-Cadherin 
interacts with β-Catenin in cell junctions and it is reduced in aggressive and metastatic 
tumors [86]. As part of the normal cellular adhesion process, E-Cadherin negatively 
regulates β-Catenin signaling by sequestering β-Catenin to the cell surface and preventing 
the Wnt signaling cascade [87]. The loss of E-cadherin causes morphologic changes such 
as cell-cell recognition, remodeling of the cytoskeleton, and loss of surface adhesion [87]. 
The present study investigates the mechanism of NEDD9 as a key regulator in FAK/Src 
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and Wnt/β-Catenin/E-Cadherin signaling that exacerbates migration, invasion and 
metastasis in Cr(VI)-transformed cells. 
2.3 Methods 
2.3.1 Chemicals and Reagents 
Dulbecco’s Modified Eagle Medium (DMEM), Opti-MEM, fetal bovine serum 
(FBS), Lipofectamine 3000, Oligo(dT)20 and puromycin were purchased from Invitrogen 
(Valencia, CA). HuSH pGFP-V-RS shNEDD9 plasmid was purchased from OriGene 
(Rockville, MD). Src plasmid was purchased from Addgene and created by Dr. Yamaki 
[88]. The dual site inhibitor SrcI1 was purchased from Sigma-Aldrich (St Louis, MO). β- 
Catenin inhibitor IWP4 was purchased from Tocris (Minneapolis, MN). Antibodies 
against NEDD9, Src, p-Src (Y416), FAK, β-Catenin, non-p-β-Catenin (active), GSK-3β, 
and p-GSK-3β (21/9) were purchased from Cell Signaling Technologies (Beverly, MA). 
Antibodies against GAPDH, E-Cadherin, and p-GSK-3β (279/216) were purchased from 
Santa Cruz (San Diego, CA). Antibodies against p-FAK (Y397) were purchased from 
Millipore. Secondary mouse, rabbit, and goat antibodies were purchased from Sera Care 
(Milford, MA). Enhanced chemiluminescence reagent was purchased from GE 
Healthcare. RNeasy mini kit was purchased from Qiagen (Valencia, CA). Moloney 
murine leukemia virus (M-MLV) reverse transcriptase and Serine-threonine GSK3-β 
Kinase Assay kit were purchased from Promega (Madison, WI). qScript cDNA synthesis 
kit and Perfecta SYBR Green Supermix were purchased from Quanta Biosciences 
(Gaithersburg, MD). Human Soluble E-Cadherin ELISA kit was purchased from 
Aviscera Bioscience (Santa Clara, CA). 
2.3.2 Cell Culture 
Human bronchial epithelial (BEAS-2B) cells were purchased from American 
Type Culture Collection (Rockville, MD). The cells were maintained in DMEM media 
with 10% fetal bovine calf serum (FBS) and 1% penicillin-streptomycin. Cr(VI)- 
transformed cells were generated by chronic exposure of BEAS-2B cells to a low dose of 
Cr(VI). Fresh media were added every 3 days for 24 weeks. Single colonies were isolated 
using a Soft Agar assay as previously described [26] and continued to grow. Those cells 
are considered as Cr(VI)-transformed cells. Passage matched normal BEAS-2B cells 
without Cr(VI) exposure were used as control. 
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2.3.3 Stable NEDD9 knockdown cells 
Cr(VI)-transformed BEAS-2B cells were seeded at 2 x 106 cells in 10cm cell culture dishes. 
The cells were transfected with NEDD9 shRNA plasmids using Lipofectamine 3000 in 
Opti-MEM. After selection with puromycin for 3 weeks, the single clones were isolated 
and NEDD9 level was confirmed by immunoblotting analysis. 
2.3.4 Immunoblotting analysis 
Whole cell lysate was prepared in RIPA buffer. The protein concentration was 
assessed using Bradford protein assay at absorbance 595 nm measured on iMark 
microplate reader (Bio-Rad). Proteins were separated by SDS-PAGE using 10% 
acrylamide gels followed by overnight incubation in primary antibodies. The blots were 
then re-probed with secondary antibodies conjugated to horseradish peroxidase. Proteins 
were visualized using an enhanced chemiluminescence kit. 
2.3.5 Immunoprecipitation 
Briefly, 500 μg of whole cell lysate was pre-cleared with protein G beads at 4°C 
for 1 hour. The supernatant was incubated in primary antibodies overnight. Protein G 
beads were added and the targeted protein complexes were precipitated using 
centrifugation. Protein complexes were analyzed with immunoblotting techniques. 
2.3.6 Real time PCR 
Briefly, RNA was extracted and purified using Qiagen RNeasy mini kit. cDNA 
synthesis was performed using Oligo(dT)20 and M-MLV reverse transcriptase. Primers 
were designed using Primer-Blast with forward sequence (F) and reverse (R) as follows: 
NEDD9: F-CCCATCCAGATACCAAAAGGACG, R- 
CACTGGAACTGAAAACACAGGGC GAPDH: F- 
GTCTCCTCTGACTTCAACAGCG, R-ACCACCCTGT TGCTGTAGCCAA 
ECadherin: F-GCCTCCTGAAAAGAGAGTGGAAG, 
RTGGCAGTGTCTCTCCAAATCCG Real time PCR was performed using Perfecta 
SYBR Green Supermix (Bio-Rad) and the data were analyzed using CFX Manager 
software (Bio-Rad). 
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2.3.7 Migration and Invasion assays 
Migration and invasion assays were performed using transwell chambers from 
Corning. Cells were seeded in serum free media at 8 x 104 cells per chamber with pre- 
warmed Matrigel coating (invasion) and without Matrigel coating (migration). Chambers 
were inserted into a 24-well plate containing 20% FBS for 24 hours. The migrated or 
invaded cells were stained with crystal violet and counted using microscope (Olympus). 
2.3.8 ELISA assay 
Soluble E-Cadherin was detected using a human soluble E-Cadherin ELISA assay 
kit according to manufacturer instructions. Briefly, 200 μL of supernatant from the cells 
was added to the wells and incubated for 24 hours. Next biotin and streptavidin were 
added. TMB One-Step substrate (3,3’,5,5’-tetramentylbenzidine) was added for detection 
with horseradish peroxidase. The absorbance was measured using iMark microplate 
reader (Bio-Rad) at 450 nm. 
2.3.9 Kinase activity assay 
GSK-3β kinase activity was analyzed using Serine-threonine GSK3-β Kinase 
Assay. Briefly, whole cell lysates were prepared in RIPA buffer and incubated with 
GSK-3β substrate and ATP in 96-well plates. ADP-Glo was added to stop the kinase 
reaction and to deplete all unconsumed ATP. ADP luminescent detection reagent was 
added to generate thermostable luciferase. The luminescence was measured by 
chemiluminescence using Spectra Max GEMINI microplate reader (Molecular Devices). 
2.3.10 In vivo tail vein injection assay 
6-week-old female athymic nude mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). The animals were handled in accordance to the 
institutional animal care and use committee (IACUC) guidelines and housed in the 
Chandler Medical Center, University of Kentucky. 0.5 x 106 cells suspended in 150 μL of 
PBS were injected into the lateral tail vein. At 8 weeks of post injection, mice were 
euthanized using CO2 and lungs were isolated. 
2.3.11 Statistical analysis 
Data were expressed as the mean ± standard deviation. Statistical significance of 
differences between treatment groups was determined by ANOVA when there were 
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multiple independent variables, and Student’s t-test when there was a single variable. Α p 
< 0.05 was considered statistically significant. 
2.4 Results 
2.4.1 Upregulation of NEDD9 in Cr(VI)-transformed BEAS-2B cells. 
Our previous studies have shown that chronic exposure to Cr(VI) causes 
malignant cell transformation in human bronchial epithelial BEAS-2B cells [26]. These 
transformed cells exhibit reduced ROS generation and resistance to apoptosis, resulting in 
increased angiogenesis and tumorigenesis . The present study examines the mechanism of 
migration and invasion of Cr(VI)-transformed cells. To investigate aggressiveness of 
these Cr(VI)-transformed cells, a known gene important in migration and invasion was 
examined. Emerging evidence has suggested that neuronal precursor developmentally 
down-regulated 9 (NEDD9) is a critical mediator for increased migration, invasion and 
metastasis [34, 42, 44, 71, 75, 78, 80, 92]. The NEDD9 level in Cr(VI)-transformed cells 
was measured to see if this scaffolding protein was upregulated in Cr(VI)-transformed 
cells. The results from Immunoblotting analysis showed that the NEDD9 level was 
elevated in Cr(VI)-transformed cells (Figure 1A). The results from RT-PCR showed that 
NEDD9 mRNA level was increased 2.9-fold in Cr(VI)-transformed cells compared to 
that in passage-matched normal cells (Figure 1B). These results demonstrate that NEDD9 
protein and mRNA levels were increased in Cr(VI)-transformed cells. 
2.4.2 Knockdown of NEDD9 reduces migration and invasion in Cr(VI)-transformed 
cells. 
The scaffolding protein NEDD9 along with other Cas family proteins have been 
shown in the literature to increase cellular migration and invasion through several 
different mechanisms [79]. Next, we investigated whether upregulation of NEDD9 is 
involved in migration and invasion in Cr(VI)-transformed cells. Stable NEDD9 
knockdown in Cr(VI)-transformed cells were established. NEDD9 level was measured 
and the results showed that NEDD9 was markedly reduced in NEDD9 knockdown cells 
(shNEDD9) compared to that in Cr(VI)-transformed scramble cells (Figure 2A). The 
results from the Boyden chamber assay showed a 41% decrease in NEDD9 knockdown 
cells compared to that in Cr(VI)-transformed scramble cells (Figure 2B). Likewise, the 
results from the invasion assay showed a 73% decrease in NEDD9 knockdown cells 
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compared to that in Cr(VI)-transformed scramble cells (Figure 2C). These results 
demonstrated that NEDD9 is important in the migration and invasion of Cr(VI)- 
transformed cells. There was no significant difference in cell proliferation between 
Cr(VI)-transformed cells and shNEDD9 cells (data not shown). 
2.4.3 Knockdown of NEDD9 reduces metastasis in vivo. 
To study if upregulation of NEDD9 positively regulated metastasis of Cr(VI)- 
transformed cells, Cr(VI)-transformed cells with or without NEDD9 knockdown were 
injected into the tail vein of athymic nude mice. Tail vein injections are a well- 
established approach used in metastasis research with a quicker outcome than 
subcutaneous or specific site injections [93]. Multiple metastatic tumors were found in 
the lungs of the animals injected with Cr(VI)-transformed cells (Figure 3A). All six 
animals injected with Cr(VI)-transformed cells that made it to the endpoint developed 
tumors in the lungs. 1-59 visible tumors were observed on each lung of the mice injected 
with Cr(VI)-transformed cells. Among the animals injected with NEDD9 knockdown 
cells (Figure 3B), 3 animals did not grow visible tumors and 4 grew 1-2 visible tumors on 
the lungs. Besides the metastatic tumors in the lungs, multi-tumors were observed in the 
liver of animals injected with Cr(VI)-transformed cells (data not shown). These results 
demonstrated that NEDD9 is a positive regulator of aggressiveness in vivo of Cr(VI)- 
transformed cells. 
2.4.4 Upregulation of NEDD9 increases aggressiveness by facilitating FAK/Src binding 
and active Src (Y416). 
To understand the mechanisms of NEDD9 in regulation of migration and invasion 
of Cr(VI)-transformed cells, several commonly associated binding partners of NEDD9 
were evaluated. The ability of NEDD9 to bind with FAK and Src has been shown to 
cause increased aggressiveness phenotypes in some cancers, and we examine if this may 
be true in Cr(VI)transformed BEAS-2B cells. The results from immunoblotting showed 
that expressions of both FAK and p-Src Y416 were increased in Cr(VI)-transformed cells 
(Figure 4A). Knockdown of NEDD9 by its shRNA reduced FAK and the 
phosphorylation of Src (Figure 4A). The results from the co-IP assay showed that binding 
of NEDD9 with FAK (Figure 4B) and with Src (figure 4C) was increased in Cr(VI)- 
transformed cells. Co-IP revealed that binding of FAK with Src in Cr(VI)-transformed 
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cells was increased (Figures 4D). Knockdown of NEDD9 by its shRNA dramatically 
reduced the binding of FAK with Src (Figure 4D). These results demonstrate that 
NEDD9 is a vital component of FAK and Src interaction and subsequent Src activation. 
2.4.5 Upregulation of NEDD9 increases aggressiveness by increasing active non- 
phosphorylated β-Catenin through GSK-3β activity. 
β-Catenin interacts with cadherin molecules in adhesion junctions [94]. Loss of E- 
Cadherin and release of β-Catenin is commonly observed in anchorage independent 
cancer cell [94]. The results showed that Full length E-Cadherin was increased as we 
would expect in BEAS-2B cells, and reduced in Cr(VI)-transformed cells (Figure 5A). 
The mRNA levels were significantly decreased in Cr(VI)-transformed cells compared to 
those in passage-matched normal BEAS-2B cells (Figures 5B). However, inhibition of 
NEDD9 by its shRNA did not alter E-Cadherin protein or mRNA levels (Figures 5A and 
5B). Interestingly, cleaved E-Cadherin was much higher in Cr(VI)-transformed cells and 
significantly reduced by NEDD9 knockdown (Figure 5A). Cleaved E-Cadherin functions 
as a paracrine signaling ligand or an intracellular signaling molecule to promote cancer 
cell motility, invasion [53] and activation of β-Catenin [95]. This cleaved form of E- 
Cadherin can be either soluble or intracellular. To discern which cleaved fragment is 
expressed, an ELISA assay was performed to measure soluble E-Cadherin excreted from 
the cells (Figure 5C). There was no significant difference of soluble E-Cadherin between 
Cr(VI)-transformed cells and passage-matched normal cells which implies the observed 
cleaved E-Cadherin are intracellular fragments (Figure 5C). Next, β-Catenin was 
measured. Active β-Catenin was elevated in Cr(VI)-transformed cells and knockdown of 
NEDD9 reduced active β-Catenin (Figure 5D). GSK-3β is a negative regulator for β- 
Catenin in the β-Catenin destruction complex. The results showed that both GSK-3β 
phosphorylation (Figure 5D) and kinase activity (Figure 5E) were reduced in Cr(VI)- 
transformed cells compared to those in passage-matched BEAS-2B cells. Inhibition of 
NEDD9 by its shRNA increased GSK-3β phosphorylation and kinase activity (Figures 
5D and 5E). These results demonstrate that NEDD9 negatively regulates GSK-3β kinase 
activity, therefore positively regulated β-Catenin, and that Cleaved E-Cadherin seems to 
pool in Cr(VI)transformed cells having possible effects on the role of β-Catenin in 
cellular signaling. 
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2.4.6 Src and β-Catenin are downstream targets of NEDD9 in regulation of migration 
and invasion in Cr(VI)-transformed cells. 
To explore whether NEDD9 regulates migration and invasion through Src and β- 
Catenin, Src and β-Catenin were inhibited using the gold standard c-Src inhibitor SrcI1 
and the potent Wnt/β-Catenin inhibitor IWP4. Interestingly, active non-phosphorylated β- 
Catenin was significantly decreased in response to both β-Catenin and Src inhibition 
(Figure 6A). As expected, active p-Src (Y416) was decreased when treated with SrcI1 
(Figure 6A). Cr(VI)-transformed cells treated with either SrcI1 or IWP4 exhibited 
significantly reduced migration and invasion (Figures 6B and 6C). To confirm that Src 
was downstream of NEDD9 in the processes of migration and invasion, Src was 
transfected into NEDD9 knockdown Cr(VI)-transformed cells (Figure 6D). Forced 
expression of Src increased migration and invasion in Cr(VI)-transformed cells with 
NEDD9 knockdown (Figures 6E and 6F). These results suggested that both Src and β- 
Catenin are involved in migration and invasion of Cr(VI)-transformed cells. The decrease 
in β-Catenin when treated with SrcI1 is indicative of cross talk between the Src and β- 
Catenin signaling pathways. 
2.4.7 Scheme of mechanism of aggressiveness in Cr(VI)-transformed cells. 
Exposure to Cr(VI) causes malignant cell transformation. These transformed cells 
have a characteristic decrease of C-PARP and Bax, and increase of Bcl-2, Bcl-xL, and 
active EGFR. A stable Cr(VI)-transformed cell line was generated from a single clone. 
These Cr(VI)-transformed cells exhibit increased NEDD9. This increase of NEDD9 
facilitated activation of Src kinase, and FAK-Src binding. NEDD9 was able to increase 
active β-Catenin in these chromium transformed cells likely by reducing GSK-3β kinase 
activity. There was an elevation of cleaved E-Cadherin which was likely involved in β- 
Catenin activity and pooling in the cytosol. NEDD9 mediates migration and invasion 
through Src and β-Catenin in Cr(VI)-transformed cells. 
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2.5 Discussion 
Cr(VI) exposure has long been known to have carcinogenic effects [67] with strong 
epidemiologic evidence [7, 96, 97]. Although great progress in understanding 
mechanisms of Cr(VI) has been made, the mechanism of aggressiveness of Cr(VI)- 
transformed cells is largely unknown. Our previous study demonstrated that Cr(VI)- 
transformed cells are tumorigenic [26]. The present study intended to investigate (1) 
whether migration and invasion are increased in Cr(VI)-transformed cells and (2) what is 
the mechanism to cause increased migration and invasion of Cr(VI)-transformed cells. 
This study provided new insights into aggressiveness of Cr(VI)-transformed cells by 
focusing on cross-talk between the FAK/Src and the Wnt signaling pathways. 
Our results of NEDD9 upregulation in Cr(VI)-transformed cells agree with 
previous reports that NEDD9 acts as upstream of FAK and Src kinase [34, 72, 98]. 
However, several studies indicated that NEDD9 is downstream of FAK and Src [41, 99]. 
Thus, a positive feedback loop between NEDD9 and FAK or Src activation through 
phosphorylation was proposed [34]. In Cr(VI)-transformed cells, the presence of NEDD9 
is essential for FAK/Src binding as demonstrated by the results in Figure 4D. The direct 
binding of NEDD9 with FAK and Src, and the inhibition FAK/Src complex when 
NEDD9 is knocked down indicates that the order of action is NEDD9/FAK/Src or 
NEDD9/Src/FAK with downstream effects inducing cellular migration and invasion. 
The interaction between FAK and Src is a common point of convergence for 
adhesion and extracellular matrix signaling in cancer [38]. Active FAK and Src most 
often leads to more aggressive tumors [100]. Indeed, FAK and Src are elevated in Cr(VI)- 
transformed cells, but our results suggested that NEDD9 is vitally important upstream of 
FAK and Src interaction. It has been reported that Y397 is the primary 
autophosphorylation site for FAK activation and opening the Src binding pocket for Src 
phosphorylation at Y416 and further activation of both FAK and Src [101]. The 
phosphorylation of Src at Y416 was nearly obliterated when NEDD9 was knocked down. 
It was reported that NEDD9 binds to FAK and Src via the SH3 domain in the N-terminal 
and SH2 in the serine-rich four helix bundle of the C-terminal domain of NEDD9 [39, 54, 
102-105]. Our data showed consistent binding between NEDD9 with FAK, and NEDD9 
with Src. FAK has 6 major tyrosine phosphorylation sites, 397, 407, 576, 577, 861, and 
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925 [106]. Phosphorylation of tyrosine 397 opens a binding site for Src SH2 domain and 
promotes association of Src and FAK [107]. After this initial step, Src can then 
phosphorylate the additional tyrosine sites to fully active FAK [106]. Our results showed 
the binding between FAK and Src was NEDD9 dependent. 
There are two mechanisms for cell migration and invasion in cancer cells, 
mesenchymal and amoeboid invasion [82]. Previous studies suggested that NEDD9 is 
associated with the mesenchymal type migration by acting as a scaffolding protein for 
FAK/Src signaling and β-integrin interactions to pull the cell through the extracellular 
matrix [80, 82]. Our results suggest that there is indeed direct binding between NEDD9 
and FAK, and a characteristic decrease in E-Cadherin and increased β-Catenin expression 
which is commonly seen in epithelial to mesenchymal transition (EMT). [83]Canonically, 
phosphorylated β-Catenin is associated with APC, Axin, CK1, PP2A, GSK-3β, and β- 
TrCP which then ubiquitinated β-Catenin for proteasomal degradation [83]. In many 
cancers and when Wnt signaling was activated, non-phosphorylated β-Catenin pools in 
the cytosol and nucleus to upregulate genes associated with TCF/LEF. Interestingly, 
other EMT markers such as Snail, Slug, and Twist protein levels were decreased Cr(VI)- 
transformed cells compared to those in passage-matched normal cells (data not shown). 
The question remains why some EMT markers are increased and others are decreased in 
Cr(VI)-transformed cells. It is likely that activated β-Catenin in Cr(VI)-transformed cells 
is important for increased migration and invasion, but not as a transcription factor with 
TCF/LEF for Snail, Slug and Twist transcription as seen in classical Wnt/β-Catenin 
driven EMT [108-110]. 
E-Cadherin complexes with β-Catenin in normal cellular adhesion junctions [53, 
111]. When E-Cadherin expression is lost β-Catenin is released and activates Wnt 
signaling associated with cancer survival, proliferation, and migration [112]. Cr(VI)- 
transformed exhibited decreased E-Cadherin, increased cleaved E-Cadherin, and 
increased active non-phosphorylated β-Catenin. It is likely that intracellular cleaved E- 
Cadherin is still interacting with β-Catenin to some extent to prevent β-Catenin 
translocation to the nucleus but allow pooling of β-Catenin and facilitating interactions 
with proteins close to the cell surface. Previously, active β-Catenin has been observed to 
accumulate near the cell surface in E-Cadherin knockout conditions but the mechanism 
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for recruitment to the plasma membrane had not been discover [113]. It is possible that 
interaction with intracellular cleaved E-cadherin is an important factor in β-Catenin 
recruitment to the plasma membrane. Our results showed GSK-3β kinase activity was 
reduced in Cr(VI)-transformed cells and increased when NEDD9 was knocked down 
(Figures 4H and 4I). These results indicate that NEDD9 regulates β-Catenin through 
GSK-3β. 
Our results demonstrated the possibility for cross-talk between Src and β-Catenin 
(Figure 5A). If this crosstalk is significant it will likely be important in multiple diseases 
including diabetes, cancer, and bipolar disease [114, 115]. There are still many open 
questions for the importance of NEDD9 in other diseases such as Parkinson’s, Alzymer’s, 
hypertension, and pulmonary disease [116, 117]. Further investigation is needed to 
uncover the exact link between NEDD9/FAK/Src and Wnt/β-Catenin signaling pathways. 
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Figure 2.1 Upregulation of NEDD9 in Cr(VI)-transformed BEAS-2B cells. 
 
A. Whole cell lysates from BEAS-2B and Cr(VI)-transformed cells were collected for 
immunoblotting analysis. B. NEDD9 mRNA levels from BEAS-2B and Cr(VI)- 
transformed cells were analyzed using real time PCR. *, p < 0.05 compared to passage- 
matched BEAS-2B cells. These results represent three independent repeats. 
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Figure 2.2 Knockdown of NEDD9 reduces migration and invasion in Cr(VI)- 
transformed cells. 
 
A. Cr(VI)-transformed cells with or without NEDD9 knockdown were grown in cell 
culture medium. Whole cell lysates were collected and subjected to immunoblotting 
analysis. B. Cr(VI)-transformed cells with or without NEDD9 knockdown were grown in 
cell culture medium. Migration assay was performed. C. Cr(VI)-transformed cells with or 
without NEDD9 knockdown were grown in cell culture medium. Invasion assay was 
performed. *, p < 0.05 compared to Cr(VI)-transformed cells. These results represent 
three independent repeats. 
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Figure 2.3 Knockdown of NEDD9 reduces metastasis in vivo. 
 
Cr(VI)-transformed cells with or without NEDD9 knockdown were injected 
intravenously into the lateral vein of 6-week-old nude mice. Mice were sacrificed after 8 
weeks and lungs were isolated. Pictures of lungs were captured and tumors were counted. 
n=8 for each group, 2 mice injected with Cr(VI)-transformed cells were lost before the 
endpoint, and 1 mouse injected with knockdown cells was lost before the endpoint. *, p < 
0.05 compared to Cr(VI)-transformed cells. 
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Figure 2.4 Upregulation of NEDD9 increases aggressiveness by facilitating FAK/Src 
binding and active Src (Y416). 
 
A. BEAS-2B cells and Cr(VI)-transformed cells with or without NEDD9 knockdown 
were harvested for immunoblotting analysis. B. Protein lysate was collected from BEAS- 
2B cells and Cr(VI)-transformed cells and immunoprecipitation was performed for FAK 
and NEDD9 binding. C. Protein lysate was collected from BEAS-2B cells and Cr(VI)- 
transformed cells and immunoprecipitation was performed for Src and NEDD9 binding. 
D. Protein lysate was collected from BEAS-2B cells and Cr(VI)-transformed cells with or 
without NEDD9 knockdown and immunoprecipitation was performed for FAK and Src 
binding. These results represent three independent repeats. 
34  
 
 
35  
Figure 2.5 Upregulation of NEDD9 increases aggressiveness by increasing active 
non-phosphorylated β-Catenin through GSK-3β activity. 
 
A. Protein lysate was collected from BEAS-2B cells and Cr(VI)-transformed cells for 
immunoblotting analysis. B. E-Cadherin mRNA levels from BEAS-2B cells and Cr(VI)- 
transformed cells with or without NEDD9 knockdown were measured using real time 
PCR. C. Cell culture medium from BEAS-2B cells and Cr(VI)-transformed cells with or 
without NEDD9 knockdown were collected for measurement of soluble E-Cadherin. D. 
Whole cell lysates were collected from BEAS-2B cells and Cr(VI)-transformed cells with 
or without NEDD9 knockdown for immunoblotting analysis. E. Kinase assay was used to 
detect GSK-3β kinase activity. * and #, p < 0.05 compared to BEAS-2B cells and Cr(VI)- 
transformed cells, respectively. These results represent three independent repeats. 
 
 
. 
36  
 
 
 
 
37  
Figure 2.6 Src is a downstream target of NEDD9 in regulation of migration and 
invasion in Cr(VI)-transformed cells. 
 
A-C. Cr(VI)-transformed cells were pretreated with 10 μM of Src1, 30 μM of IWP4, or 
their combination for one hour. Whole cell lysate was collected for immunoblotting 
analysis (A). Migration (B) and invasion (C) assays were performed. D-F. Cr(VI)- 
transformed cells with NEDD9 knockdown were transfected with Src expressing vector. 
Cr(VI)-transformed cells with or without NEDD9 knockdown or with Src overexpression 
as indicated were subjected to immunoblotting analysis (D), migration (E) and invasion 
(F) analysis. * and #, p < 0.05 compared to Cr(VI)-transformed cells and Cr(VI)- 
transformed cells with NEDD9 knockdown, respectively. These results represent three 
independent repeats. 
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Figure 2.7 Scheme of mechanism of aggressiveness in Cr(VI)-transformed cells. 
 
Chronic exposure of human bronchial epithelial cells to low dose of Cr(VI) causes 
malignant cell transformation. In those Cr(VI)-transformed cells expressions of NEDD9, 
Src, β-Catenin, and C-E-Cadherin were elevated. NEDD9 acts as an upstream of Src, β- 
Catenin, and C-E-Cadherin. The signaling of NEDD9/Src/β-Catenin positively regulates 
migration, invasion, and metastasis of Cr(VI)-transformed cells. 
CHAPTER 3. UPREGULATION OF NEDD9 PROMOTES ANGIOGENESIS BY INCREASING HIF- 
1𝛼𝛼 TRANSCRIPTIONAL ACTIVITY IN CHROMIUM(VI)-TRANSFORMED BRONCHIAL
EPITHELIAL CELLS 
3.1 Abstract 
Hexavalent Chromium (Cr(VI)) is a group one carcinogen, as defined by 
International Agency for Research and Cancer (IARC). Once inside the cell Cr(VI) is 
reduced to Cr(V), Cr(IV), and Cr(III) generating reactive oxygen species, carcinogenic 
DNA adducts, alterations in epigenetics, and changes in cell signaling. Neural precursor 
cell developmentally downregulated protein 9 (NEDD9) is a Cas family, scaffolding 
protein that is upregulated in Cr(VI)-transformed BEAS-2B cells. NEDD9 facilitates the 
assembly of many oncogenic signaling complexes. HIF-1α is the major inducible factor 
that responds quickly to changes in available oxygen levels in the cell. HIF-1α and HIF- 
1β translocate to the nucleus as a dimer where they link up with their cofactors p300 and 
CBP and initiate gene transcription of VEGF and other critical genes for angiogenesis 
and erythropoiesis on the hypoxia response element (HRE). HUVEC cell tubes formed 
closed loop cell aggregates 42.8% more in those exposed to Cr(VI)-transformed cell 
serum than in those exposed to BEAS-2B cell serum and 28.4% less in those exposed to 
Cr(VI)-transformed knockdown NEDD9 cell serum. NEDD9 mediated the expression of 
PECAM/CD31 (PECAM) which is involved with motility and adhesion during 
angiogenesis, Angiopoietin 1 which is critical in vascular development and angiogenesis, 
VEGF which is important in growth, recruitment, and remodeling of vasculature, HIF-1α 
which is a major inducible transcription factor for angiogenesis, and p38 which is 
involved in VEGF activity and expression. An in vivo Matrigel plug assay showed that 
Cr(VI)-transformed cell plugs contained 13.6 fold more hemoglobin than BEAS-2B cell 
plugs and that Cr(VI)-transformed cell plugs contained 2.8 fold more hemoglobin than 
Cr(VI)-transformed knockdown NEDD9 cells. HIF-1α transcriptional activity in Cr(VI)- 
transformed cells was 6.1 fold increase compared to BEAS-2B cells and 34.3 fold 
increase compared to Cr(VI)-transformed knockdown NEDD9 cells. The transcriptional 
activity of HIF-1α is mediated by NEDD9 likely through CREB binding protein (CBP) 
by directing binding to CBP in the nucleus. Additionally, the presence of NEDD9 
increases the activity of p38. Both of these will affect the production and secretion of 
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VEGF and other factors which control angiogenesis and vasculature permeability. This 
understanding is beneficial and places NEDD9 as an important therapeutic target or 
biomarker for angiogenesis. 
3.2 Introduction 
Hexavalent Chromium (Cr(VI)) is a group one carcinogen, as defined by 
International Agency for Research and Cancer (IARC). Occupational exposure to 
aerosolized Cr(VI) often accumulates in the bronchi, leading to increased risk for 
aggressive lung cancer. Cr(VI) (CrO42-) enters the cell through the sulfate channel and 
other nonspecific transporters due to its solubility and its similarities to SO42- and HPO42- 
[19]. Once inside the cell Cr(VI) is reduced to Cr(V), Cr(IV), and Cr(III) generating 
reactive oxygen species, carcinogenic DNA adducts, alterations in epigenetics, and 
changes in cell signaling. The literature has demonstrated with few exceptions that VEGF 
and angiogenic markers are upregulated in cells treated with Cr(VI) [33, 118, 119]. 
Neural precursor cell developmentally downregulated protein 9 (NEDD9) is a Cas 
family scaffolding protein that is upregulated in Cr(VI)-transformed BEAS-2B cells. 
NEDD9 is overexpressed in many aggressive cancer types including lung [71], breast 
[72], melanoma [73, 74], colon [75], liver [36], pancreatic [76, 77], prostate [78] and 
kidney [79]. NEDD9 facilitates the assembly of many oncogenic signaling complexes. 
The concentration of this paper will be angiogenesis, but NEDD9 has been implemented 
in focal adhesion, cell cycle checkpoints, lamellipodia formation, and immune control to 
name a few [80]. 
In this study we examine how NEDD9 is involved in angiogenesis in Cr(VI)- 
transformed BEAS-2B cells. NEDD9 was linked with hypoxia inducible factor-1α (HIF- 
1α) which is the major inducible transcription factor in the production of angiogenic 
proteins [59]. It has been linked to MMP secretion and membrane protein recycling as a 
critical part of angiogenesis and invasion [120]. The depletion of Cas family proteins is 
accompanied by reduced Src activation and FAK/Src dependent angiogenesis [54]. In 
addition to these major factors NEDD9 has been linked with the activity of multiple small 
GTPases such as RhoA, Rock, Nck2, and Cdc42 which are required for the sprouting of 
new vasculature [55-58]. 
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HIF-1α is the major inducible factor that responds quickly to changes in available 
oxygen levels in the cell. Under normoxia, HIF-1α is hydroxylated by the prolyl 
hydroxylase domain-containing (PHD) family proteins and associated with von hippel- 
lindau (VHL). This form of HIF-1α is ubiquitinated and sent to the proteasome for 
degradation. In the absence of oxygen PHD1 and PHD3 are degraded and HIF-1α is set 
free. HIF-1α and HIF-1β translocate to the nucleus as a dimer where they link up with 
their cofactors p300 and CBP and initiate gene transcription of VEGF and other critical 
genes for angiogenesis and erythropoiesis on the hypoxia response element (HRE) [121]. 
A tumor can only grow to be roughly 1-2 mm3 before there is a critical need for new 
vasculature. At this point the cells in the center of the tumor may start to necrose as the 
metabolic demands, nutrients, and oxygen become scarce. At this point hypoxia sets in, 
and HIF-1α is translocated to the nucleus as the initial stages of angiogenesis. In highly 
aggressive tumors HIF-1α is elevated as an important part of cell survival, growth, 
migration, and invasion [121, 122]. 
The proposal of this paper is to suggest a mechanism for Cr(VI)-transformed cell 
angiogenesis through NEDD9. NEDD9 was found to enhance HIF-1α transcriptional 
activity by interaction with the cofactor p300 in colon cancer cell lines LS174T, DLD-1, 
SW480, HCT-15, and SW620 [59]. We expect to find a similar response in Cr(VI)- 
transformed cells. 
3.3 Materials and Methods 
3.3.1 Chemicals and Reagents 
Dulbecco’s Modified Eagle Medium (DMEM), Opti-MEM, fetal bovine serum 
(FBS), Lipofectamine 3000, Oligo(dT)20 and puromycin were purchased from Invitrogen 
(Valencia, CA). HuSH pGFP-V-RS shNEDD9 vector was purchased from OriGene 
(Rockville, MD). Antibodies against NEDD9 was purchased from Cell Signaling 
Technologies (Beverly, MA). GAPDH was purchased from Santa Cruz (San Diego, CA). 
Secondary mouse and rabbit were from Sera Care (Milford, MA). Enhanced 
chemiluminescence reagent was from GE Healthcare. RNeasy mini kit was purchased 
from Qiagen (Valencia, CA). qScript cDNA synthesis kit and Perfecta SYBR Green 
Supermix were from Quanta Biosciences (Gaithersburg, MD). 
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3.3.2 Cell Culture 
Human bronchial epithelial (BEAS-2B) cells were purchased from American 
Type Culture Collection (Rockville, MD). Cells were incubated at 37 °C and 5% CO2. 
DMEM was supplemented with 10% FBS and 1% penicillin-streptomycin. Cells were 
passaged when cell density reached 80% confluency or less. Cr(VI)-transformed cells 
were generated as previously described by chronic low dose exposure of Cr(VI) to 
BEAS-2B cells [26]. 
3.3.3 Stable NEDD9 knockdown cells 
Cr(VI)-transformed BEAS-2B cells were seeded at 2 x 106 cells in 10cm cell 
culture dishes. The cells were transfected with NEDD9 shRNA plasmids using 
Lipofectamine 3000 in Opti-MEM. After selection with puromycin for 3 weeks, the 
single clones were isolated and NEDD9 levels were confirmed using immunoblotting. 
3.3.4 Immunoblotting analysis 
Whole cell lysate was prepared using RIPA buffer. The protein concentration was 
quantified by the Bradford protein assay measuring absorbance at 595 nm using iMark 
microplate reader (Bio-Rad). The proteins were separated by SDS-PAGE and probed for 
targets overnight in primary antibody incubation at 4°C. The blots were re-probed with 
secondary antibodies conjugated to horseradish peroxidase. Protein bands were visualized 
using an enhanced chemiluminescence kit. 
3.3.5 Real-time PCR 
RNA was extracted and purified using Qiagen RNeasy mini kit. The cDNA was 
synthesized by using Oligo(dT)20 and M-MLV reverse transcriptase. Primers were 
designed based on Primer-Blast with the following sequences forward (F) and reverse 
(R). 
GAPDH: F-GTCTCCTCTGACTTCAACAGCG 
R-ACCACCCTGTTGCTGTAGCCAA 
HIF-1α: F-GGCGCGAACGACAAGAAAAAG 
R-CCTTATCAAGATGCGAACTCACA 
Real time PCR was performed with Perfecta SYBR Green Supermix (Bio-Rad) and the 
data were analyzed with CFX manager software (Bio-Rad). 
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3.3.6 ELISA 
Soluble VEGF was detected using human VEGF ELISA assay kit. Briefly, 200 
μL of supernatant from the cells was added to each well and incubated for 24 hours. 
Biotin and streptavidin were added. 3,3’, 5,5’-tetramentylbenzidine substrate (TMB One- 
Step) was added for detection with horseradish peroxidase. Absorbance was measured 
using iMark microplate reader (Bio-Rad) at 450 nm. 
3.3.7 Luciferase 
Cells were seeded at 1.5 x 106 in 10 cm dishes. The cells were transfected with 
HIF-1α reporter from Panomics. After 48 hours post transfection the cells were lysed in 
luciferase cell lysis Buffer. Samples were normalized to protein level using a Bradford 
assay and 20 μL was added to each well. 100 μL of luciferase assay substrate was added 
by the plate reader to each well and the luminescence was quantified. 
3.3.8 CAM assay 
Fertilized eggs were received from the University of Kentucky Poultry Research 
Facility. They were incubated at 37°C. On day four the CAMs were transferred to flasks 
where they continued to grow until day ten. On day ten each embryo was given two 
onplants with Cr(VI)-transformed cells and two onplants with Cr(VI)-transformed 
shNEDD9 cells. The onplants were made from 64% Collagen Type II rat tail, 8% 10x 
MEM, 8% NaOH, and 20% cells 1.5 x 104 in PBS. Photos were taken each day and 
onplants were analyzed four days post deployment. 
3.3.9 Tube formation assay 
HUVEC cells were purchased from American Type Culture Collection 
(Rockville, MD). HUVEC cells were cultured in endothelial cell basal medium-2 
supplemented with 10% FBS and 1% penicillin-streptomycin. BEAS-2B cell, Cr(VI)- 
transformed cell, and Cr(VI)-transformed knockdown NEDD9 cell serum was extracted 
after 48 hours and applied to the HUVEC medium. 
3.3.10 In vivo tumorigenesis and angiogenesis assays 
6-week-old female athymic nude mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). The animals were handled according to the institutional 
animal care and use committee (IACUC) guidelines and housed in the Chandler Medical 
Center, University of Kentucky. 
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3.3.11 Statistical analysis 
Data were expressed as the mean ± the standard deviation. Statistical significance 
of the difference between means was determined by ANOVA for multiple independent 
variables, and by Student’s t-test for single variables. A p < 0.05 was considered to be 
statistically significant. 
3.4 Results 
3.4.1 Angiogenesis is increased in Cr(VI)-transformed BEAS-2B cells. 
To explore angiogenesis in hexavalent chromium (Cr(VI)) transformed cells, new 
tube formation was measured. BEAS-2B cells and Cr(VI)-transformed cells were grown 
to 80% confluency and the serum from those cells was added to human umbilical vein 
endothelial cells (HUVEC). Tubes formed closed loop cell aggregates in those HUVEC 
cells exposed to Cr(VI)-transformed cell serum 42.8% more than in those cells exposed 
to BEAS-2B cell serum (Figure 1A). To further solidify our understanding of Cr(VI)- 
transformed cell angiogenesis an ex ovo Chick Chorioallantoic Membrane (CAM) assay 
was performed. CAMs were transferred to a dish on day 4 and incubated at 37°C. On day 
10 two onplants were added to the CAMs, one harboring BEAS-2B cells while the other 
harbored Cr(VI)-transformed cells. Images were taken on day 10, 11, 12, 13, and 14 and 
the vasculature recruited into each onplants was quantified on day 14. A 2.0 fold increase 
in vascular formation was found in the Cr(VI)-transformed cell onplants Figure 1B). 
Next, angiogenic protein markers were analyzed by western blot. There was an increased 
expression of PECAM/CD31 (PECAM) which is involved with motility and adhesion 
during angiogenesis, Angiopoietin 1 which is critical in vascular development and 
angiogenesis, VEGF which is important in growth, recruitment, and remodeling of 
vasculature, and HIF-1α which is a major inducible transcription factor for angiogenesis 
(Figure 1C). The protein kinase p38 has been found to upregulate several of these 
angiogenic factors. To see if p38 might be involved in Cr(VI)-transformed cell 
angiogenesis a western blot was performed. Phosphorylated p38 (T180/Y182) was 
increased dramatically in Cr(VI)-transformed cells (Figure 1D). 
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3.4.2 Inhibition of NEDD9 reduces angiogenesis in Cr(VI)-transformed cells. 
To explore the role of NEDD9 in hexavalent chromium (Cr(VI)) transformed 
cells angiogenesis, new tube formation was measured. Cr(VI)-transformed cells and 
Cr(VI)-transformed knockdown NEDD9 cells were grown to 80% confluency and the 
serum from those cells was added to human umbilical vein endothelial cells (HUVEC). 
Tubes formed closed loop cell aggregates in those HUVEC cells exposed to Cr(VI)- 
transformed cell serum 28.4% more than in those cells exposed to Cr(VI)-transformed 
knockdown NEDD9 cell serum (Figure 2A). To further study this phenomenon, an ex 
ovo Chick Chorioallantoic Membrane (CAM) assay was performed. CAMs were 
transferred to a dish on day 4 and incubated at 37°C. On day 10, two onplants were added 
to the CAMs, one harboring Cr(VI)-transformed cells while the other harbored Cr(VI)- 
transformed knockdown NEDD9 cells. Images were taken on day 10, 11, 12, 13, and 14 
and the vasculature recruited into each onplants was quantified on day 14. A 39.7 fold 
decrease in vascular formation was found in the Cr(VI)-transformed knockdown NEDD9 
cell onplants (Figure 2B). Next, angiogenic protein markers were analyzed by western 
blot. There was a decreased expression of PECAM, Angiopoietin 1, VEGF, and HIF-1α 
(Figure 2C). To see if p38 might be involved downstream of NEDD9, a western blot was 
performed. Phosphorylated p38 (T180/Y182) was increased dramatically in Cr(VI)- 
transformed knockdown NEDD9 cells (Figure 2D). To measure secreted VEGF an 
ELISA assay was performed. The results showed that Cr(VI)-transformed secreted 99.9% 
more VEGF than BEAS-2B cells, and that Cr(VI)-transformed cells secreted 49.6% more 
VEGF than Cr(VI)-transformed knockdown NEDD9 cells. 
3.4.3 NEDD9 increases tumorigenesis and angiogenesis. 
To determine if NEDD9 is involved tumor formation in vivo a subcutaneous, 
mouse model was used. 4 x 106 cells were injected into the flanks of 2-week-old athymic 
nude mice. Tumors were harvested 7 weeks post injection. The results showed that 
Cr(VI)-transformed cells formed tumors that were 5.3 fold larger (Figure 3B) and 3.9 
fold heavier (Figure 3C) than Cr(VI)-transformed knockdown NEDD9 cells (Figure 3A). 
The formation of much larger tumors may be due in large part to increased angiogenesis. 
To test whether Cr(VI)-transformed cells display greater angiogenesis in vivo a Matrigel 
plug assay was performed. 5 x 106 cells suspended in Matrigel and PBS were injected 
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into the flanks of 2-week-old athymic nude mice. Plugs were harvested after 10 days. 
Hemoglobin was quantified using Drabkin’s reagent. The results showed that Cr(VI)- 
transformed cell plugs contained 13.6 fold more hemoglobin than BEAS-2B cell plugs 
and that Cr(VI)-transformed cell plugs contained 2.8 fold more hemoglobin than Cr(VI)- 
transformed knockdown NEDD9 cells (Figure 3D and 3E). 
3.4.4 NEDD9 increases angiogenesis by mediating HIF-1α transcriptional activity. 
HIF-1α transcriptional activity is arguably the most important step for angiogenesis 
in cancer cells. To determine the role of NEDD9 as it relates to HIF-1α a luciferase assay 
was performed. The results showed a HIF-1α transcriptional activity in Cr(VI)- 
transformed cells with 6.1 fold increase compared to BEAS-2B cells and Cr(VI)- 
transformed cells 34.3 fold increase compared to Cr(VI)-transformed knockdown 
NEDD9 cells (Figure 4A). The next question would be if HIF-1α is upregulated at the 
mRNA level. This was measured by real-time PCR. The results showed that Cr(VI)- 
transformed cells had 54% increased HIF-1α mRNA expression and Cr(VI)-transformed 
knockdown NEDD9 cells had 99% increased HIF-1α expression compared to BEAS-2B 
cells (Figure 4B). Since there was not a decrease in HIF-1α mRNA expression in Cr(VI)- 
transformed knockdown NEDD9 cells the method for reduced transcriptional activity 
must be examined. To investigate direct binding with NEDD9 and HIF-1α and its 
cofactor CREB-binding protein (CBP) an immunoprecipitation (IP) assay was performed. 
The results showed that NEDD9 binds directly with CBP (Figure 4C). Next we 
investigated whether NEDD9, HIF-1α, and CBP were translocated to the nucleus in each 
cell type. The results show that NEDD9 can translocate to the nucleus (Figure 4D). CBP 
was also expressed much higher in the nucleus in Cr(VI)-transformed cell than BEAS-2B 
or Cr(VI)-transformed knockdown NEDD9 cells. HIF-1α was measured much higher in 
the nucleus of Cr(VI)-transformed cells than BEAS-2B or Cr(VI)-transformed 
knockdown NEDD9 cells. 
3.5 Discussion 
Hexavalent chromium (Cr(VI)) can cause the overexpression of multiple proteins 
leading to an aggressive tumor burden. Cr(VI) can cause these changes in cellular 
processes by generating reactive oxygen species, carcinogenic DNA adducts, alterations 
48  
in epigenetics, and changes in cell signaling. Neural precursor cell developmentally 
downregulated protein 9 (NEDD9) was found dramatically overexpressed in Cr(VI)- 
transformed BEAS-2B cells. This Cas family scaffolding protein is upregulated in many 
cancers and its importance in Cr(VI)-transformed cell aggressiveness is evident by the its 
role in angiogenesis. 
Arguably the most important transcription factor in angiogenesis is HIF-1α. When 
HIF-1α is translocated to the nucleus, it has the ability to transcribe some 60 or so genes 
involved in angiogenesis including VEGF, which is vital for the recruitment of new 
vasculature into a tumor. This process is vital to the growth and survival of a tumor and 
also has implications for allowing cells from the tumor to easily enter the circulatory 
system. NEDD9 was found to be very important in the transcriptional activity of HIF-1α, 
but the exact mechanism is still not completely clear. This study illustrates clearly that 
NEDD9 can mediate the transcriptional activity of HIF-1α. While the exact mechanism is 
not clear, it is obvious that there is direct binding with NEDD9 and CBP but not with 
HIF-1α. This indicates that the role of NEDD9 in the processes of angiogenesis is likely 
through activating this cofactor of HIF-1α in the nucleus to increase transcription of 
angiogenic proteins. 
CREB-binding protein (CBP) is a homologous transcription adapter with p300, and 
is active in many transcriptional events [123]. CBP often interacts with the basal 
transcriptional machinery and various transcription factors to increase transactional 
efficiency. CBP and p300 have been found to form a DNA binding complex with HIF-1α 
as well as many other oncogenic factors including jun, fos, SRC-1, and RAR-α to name a 
few [123]. There is a dramatic increase of HIF-1α transcriptional activity in the presence 
of NEDD9. Although there was no binding between NEDD9 and HIF-1α directly, the 
binding of NEDD9 and CBP indicates that this may be the mechanism by which HIF-1α 
is regulated. This would explain how angiogenesis is greatly reduced when NEDD9 is 
inhibited by its shRNA. Since CBP is primarily found in the nucleus it is likely that when 
NEDD9 is highly expressed it is also expressed in the nucleus and the interaction with 
CBP and NEDD9 would be only moments before its coactivation of HIF-1α. 
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VEGF is one of the major downstream targets for the HIF-1α transcription factor. 
It is involved in several cellular processes, but is perhaps most notable for its role in 
angiogenesis. VEGF plays a role in gene expression for new vasculature, regulates 
vasculature permeability, and promotes cell migration, proliferation, and survival [124]. 
VEGF is a ligand that binds to the VEGF-R resulting in the activation of several key 
signaling pathways. These pathways include Ras/MAPK for the regulation of cell 
proliferation, FAK/paxillin to initiate cytoskeletal rearrangement, and RhoA/ROCK to 
aid in the formation of new vasculature [125, 126]. In Cr(VI)-transformed cells VEGF 
expression, and excretion was increased. The inhibition of NEDD9 reduced VEGF 
expression and excretion having downstream effects on the recruitment of new 
vasculature and likely cell proliferation, survival and vascular permeability as well, 
though these were not measured in this study. 
The presence of NEDD9 also seemed to have a dramatic effect in the activation of 
p38. The protein p38 is a mitogen-activated protein kinase (MAPK) that has been found 
to increase angiogenesis in both cancer cells and endothelial cell response to angiogenic 
signaling. When HUVEC cells are treated with VEGF, p38 becomes activated and 
pharmaceutical inhibition of p38 attenuated VEGF induced cellular migration [65, 127, 
128]. Since the knockdown of NEDD9 greatly reduced the phosphorylation of p38, it is 
possible that NEDD9 is involved in the angiogenic process from two angles. NEDD9 can 
mediate angiogenesis by reducing the production and release of VEGF form the cancer 
cells. Secondly, if NEDD9 was targeted systemically the effects would reduce 
angiogenesis by inhibiting the endothelial response to VEGF though p38. 
This study shows that NEDD9 can mediate angiogenesis in vitro and in vivo in 
Cr(VI)-transformed cells. It presents the possible mechanism of action that NEDD9 is 
increasing HIF-1α transcriptional activity by binding with CBP. Additionally, the 
presence of NEDD9 increases the activity of p38. Both of these will affect the production 
and secretion of VEGF and control angiogenesis and vasculature permeability. This 
understanding is beneficial and places NEDD9 as an important therapeutic target or 
biomarker for angiogenesis. Further research must be done before NEDD9 can be a 
viable clinical target, but the evidence in the literature, and the evidence presented here 
shows that the research on NEDD9 should continue to expand. 
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Figure 3.1 Angiogenesis is increased in Cr(VI)-transformed BEAS-2B cells. 
 
A. BEAS-2B and Cr(VI)-transformed BEAS-2B cells were grown for two days to 80% 
confluency in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin. The 
cells were incubated in 37°C and 5% CO2. HUVEC cells were cultured in endothelial cell 
basal medium-2 supplemented with 10% FBS and 1% penicillin-streptomycin. The cells 
were incubated in 37°C and 5% CO2. Serum from BEAS-2B and Cr(VI)-transformed 
cells was added to the HUVEC samples and incubated for less than 12 hours. Closed loop 
cell aggregates were quantified. B. Fertilized eggs were incubated at 37°C for four days. 
The CAMs were transferred to flasks where they continued to grow until day ten. On day 
ten each CAM was given two onplants with BEAS-2B cells and two onplants with 
Cr(VI)-transformed cells. Photos were taken each day and onplants were analyzed four 
days post-deployment. C. Whole cell lysates were collected from BEAS-2B and Cr(VI)- 
transformed cells and angiogenic factors were analyzed by western blot. D. Whole cell 
lysates were collected from BEAS-2B and Cr(VI)-transformed cells and p38 was 
analyzed by western blot. * represents statistical significance of p < 0.05. Data were 
expressed as the mean ± the standard deviation. Difference between means was 
determined by the Student’s t-test. The results for A and B represent three independent 
repeats. The results for C and D represent single experiments. 
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Figure 3.2 Inhibition of NEDD9 reduced angiogenesis in Cr(VI)-transformed BEAS- 
2B cells. 
 
A. Cr(VI)-transformed BEAS-2B cells and Cr(VI)-transformed knockdown NEDD9 
BEAS-2B cells were grown for two days to 80% confluency in DMEM supplemented 
with 10% FBS and 1% penicillin-streptomycin and were incubated in 37°C and 5% CO2. 
HUVEC cells were cultured in endothelial cell basal medium-2 supplemented with 10% 
FBS and 1% penicillin-streptomycin and were incubated in 37°C and 5% CO2. Serum 
from and Cr(VI)-transformed and Cr(VI)-transformed knockdown NEDD9 cells was 
added to the HUVEC samples and incubated for less than 12 hours. Closed loop cell 
aggregates were quantified. B. Fertilized eggs were incubated at 37°C for four days. The 
CAMs were transferred to flasks where they continued to grow until day ten. On day ten 
each CAM was given two onplants with Cr(VI)-transformed cells and two onplants with 
Cr(VI)-transformed shNEDD9 cells. Photos were taken each day and onplants were 
analyzed four days post deployment. C. Whole cell lysates were collected from Cr(VI)- 
transformed and Cr(VI)-transformed shNEDD9 cells and angiogenic factors were 
analyzed by western blot. D. Whole cell lysates were collected from Cr(VI)-transformed 
cells and Cr(VI)-transformed shNEDD9 cells and p38 was analyzed by western blot. E. 
Serum was collected from BEAS-2B, Cr(VI)-transformed and Cr(VI)-transformed 
shNEDD9 cells and an ELISA assay was conducted. * represents statistical significance 
of p < 0.05. Data were expressed as the mean ± the standard deviation. Difference 
between means was determined by ANOVA for multiple independent variables, and by 
Student’s t-test for single variables. The results for A, B, and E represent three 
independent repeats. The results for C and D represent individual experiments. 
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Figure 3.3 NEDD9 increases tumorigenesis and angiogenesis in vivo. 
 
A. Cr(VI)-transformed BEAS-2B cells and Cr(VI)-transformed knockdown NEDD9 
BEAS-2B cells were grown for two days to 80% confluency in DMEM supplemented 
with 10% FBS and 1% penicillin-streptomycin and were incubated in 37°C and 5% CO2. 
6-week-old athymic mice were injected with 4 x 106 cells suspended in PBS in the rear 
flanks. Tumors were harvested 7 weeks post injection. B. Tumors length and width were 
measured and volume was calculated mm3 = ½(L X W2). C. Tumors were weighed in 
grams. D. Cr(VI)-transformed BEAS-2B cells and Cr(VI)-transformed knockdown 
NEDD9 BEAS-2B cells were grown for two days to 80% confluency in DMEM 
supplemented with 10% FBS and 1% penicillin-streptomycin and were incubated in 37°C 
and 5% CO2. 6-week-old athymic mice were injected with 5 x 106 cells suspended in 
Matrigel in the rear flanks. Plugs were harvested 10 days post injection. E. Hemoglobin 
was quantified using Drabkin’s reagent. * and # represents statistical significance of p < 
0.05. Data were expressed as the mean ± the standard deviation. Difference between 
means was determined by ANOVA for multiple independent variables, and by Student’s 
t-test for single variables. The results in Figure A, B, and C represent six mice three were 
injected with Cr(VI)-transformed cells and three were injected with Cr(VI)-transformed 
shNEDD9 cells. The results from D and E represent eight mice injected on each flank. 
Six Cr(VI)-transformed plugs were injected, six Cr(VI)-transformed shNEDD9 plugs 
were injected, and four BEAS-2B plugs were injected. 
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Figure 3.4 NEDD9 increases angiogenesis by mediating HIF-1α transcriptional 
activity via CBP. 
 
A. BEAS-2B, Cr(VI)-transformed and Cr(VI)-transformed shNEDD9 cells were 
transfected with HIF-1α luciferase reporter. After 48 hours the transient transfection was 
complete. Cells were lysed and the luminescence was quantified. B. mRNA was 
extracted from BEAS-2B, Cr(VI)-transformed, and Cr(VI)-transformed shNEDD9 cells 
using Quiagen RNeasy mini kit. mRNA levels were quantified using real-time PCR. C. 
Whole cell lysate was harvested from Cr(VI)-transformed cells and binding partners of 
NEDD9 were determined by an immunoprecipitation assay. D. A cell fractionation assay 
was used to harvest proteins from the cytosol and nucleus fractions from BEAS-2B and 
Cr(VI)-transformed cells. A western blot analysis was used to measure protein 
concentrations within each cell fraction. E. A cell fractionation assay was used to harvest 
proteins from the cytosol and nucleus fractions from BEAS-2B, Cr(VI)-transformed, and 
Cr(VI)-transformed shNEDD9 cells. A western blot analysis was used to measure protein 
concentrations within each cell fraction. * and # represents statistical significance of p < 
0.05. Data were expressed as the mean ± the standard deviation. Difference between 
means was determined by ANOVA for multiple independent variables. The results for A, 
B, and D represent three independent repeats. The results from C and E represent 
individual experiments. 
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Figure 3.5 Scheme of mechanism of angiogenesis in Cr(VI)-transformed cells. 
 
Chronic exposure to Cr(VI) leads to malignant cell transformation of BEAS-2B cells. 
These cells have an increased expression of NEDD9. The inhibition of NEDD9 by its 
shRNA reduces p38 phosphorylation. NEDD9 can bind directly to CBP. These two 
factors play a role in HIF-1α translocation to the nucleus and HIF-1α transcriptional 
activity. The VEGF cytokine is one of 60 angiogenic proteins transcribed by the HIF 
complex and has been shown to play a huge role in angiogenesis. Inhibition of NEDD9 
reduced VEGF transcription and excretion. The presence of NEDD9 in Cr(VI)- 
transformed cells leads to an increase in angiogenesis in vitro and in vivo. 
CHAPTER 4. CONCLUSIONS
4.1 Environmental and Occupation Hexavalent Chromium 
Chromium is ubiquitous on the planet, but it is rarely found in its elemental state. 
Most chromium deposits are a conglomerate of chromite ores and 20,000 tons of Cr metal 
is mined each year and used for various industrial endeavors [129]. In metallurgy 
chromium is used in creating stainless steel and other metal alloys. It is also useful for the 
processes of leather tanning, chrome plating, dyes, wood treatment, and as a refractory 
composite in extreme heat resistant bricks [130]. These important industries have been 
responsible for aerosolized chromium in the atmosphere that is especially dangerous for 
workers in those industries with long term exposure. Over the years there have been 
multiple occupational and cohort studies finding that workers exposed to chromium have 
higher rates of lung cancer. Chromate was found to accumulate primarily in the large 
bronchi with incidence of lung cancer reported as high as 49.5-fold compared with the non- 
exposed population in 1978 [5, 7, 96, 131, 132]. In response to the damaging potential of 
chromium exposure OSHA has established a limit of 0.005 mg/m2 hexavalent chromium 
in air over an 8-hour work day [133]. The occupational regulation was a great start in 
dealing with hexavalent chromium exposure, but there is still unregulated chromium 
exposure evident by the chromium content found in the hair and fingernails of individuals 
in the U.S., Canada, Poland, Japan and India [134]. Even at low doses hexavalent 
chromium causes malignant cell transformation [26]. The evidence shows that Chromate 
workers and those in industries exposed to Cr(VI) are at continual risk of cancer greater 
than the general population and these data should be considered when assessing the 
importance and relevance of Cr(VI) induced carcinogenesis. 
4.2 Hexavalent Chromium Carcinogenesis 
For the generation of Cr(VI)-transformed cells in our lab, a low dose of Cr(VI) 
(0.25μM) was used to transform BEAS-2B cells. The in vitro model dose is consistent with 
what a worker may be exposed to over the course of several days of work in OSHA 
acceptable conditions. If we assume 0.2 𝜇𝜇𝜇𝜇 𝑋𝑋 12 𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏ℎ𝑠𝑠 𝑋𝑋 0.5𝐿𝐿 𝑋𝑋 1𝑚𝑚3 𝑋𝑋 480 𝑚𝑚𝑚𝑚𝑚𝑚 =
𝑚𝑚3 𝑀𝑀𝑚𝑚𝑚𝑚 𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏ℎ 1000𝐿𝐿 𝑠𝑠ℎ𝑚𝑚𝑖𝑖𝑏𝑏 0.576 𝜇𝜇𝜇𝜇
𝑠𝑠ℎ𝑚𝑚𝑖𝑖𝑏𝑏 , an average worker might potentially be exposed to 0.011μM of Cr(VI) per 
shift. These epithelial cells were treated for 24 weeks. Then individual colonies were 
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established to generate a stable cell line [26]. The resulting transformed cells showed 
increased activation of EGFR, increased Bcl-2, Bcl-xL, and reduced Bax and C-PARP as 
markers for complete cell transformation. These cells are resistant to apoptosis and 
proliferate much more quickly than passage matched BEAS-2B cells. These Cr(VI)- 
transformed cells were the cause of tumorigenicity when xenograft in nude mice [135]. 
4.3 Hexavalent Chromium Aggressiveness 
In the field of metal carcinogenesis there have been few studies focusing on metal 
induced aggressiveness relating to migration, invasion and angiogenesis. The effects of 
Cr(VI) have been largely defined by the ability to produce massive amounts oxidative 
stress as it is reduced to Cr(V), Cr(IV), and Cr(III) by interacting with iron and other 
molecules in the cell. Through the reduction process reactive oxygen species are released 
into the cell. These Chromium compounds can be oxidized and reduced multiple times. 
This project reveals that Cr(VI)-transformed cells display a highly aggressive phenotype 
with increased migration, invasion and angiogenesis. It is apparent that NEDD9 is a vital 
contributor to the aggressive phenotype of these Cr(VI)-transformed cells. 
For the first time, a clear link between Cr(VI) exposure and migration and invasion 
has been proposed. NEDD9 was vital for the migration, invasion, and angiogenesis for 
Cr(VI)-transformed BEAS-2B cells. This establishes NEDD9 as a possible therapeutic 
target or biomarker as part of a cancer treatment strategy. Two natural chemicals were 
discovered in the duration of this project to reduce NEDD9 expression without affecting 
cell viability of normal BEAS-2B cells. Apigenin is an antioxidant that has long been used 
as a traditional herbal treatment and can be derived from various plants including parsley, 
celery, and chamomile tea. α-pinene is a second natural chemical that can be derived from 
coniferous trees and has some history as a treatment for various diseases. These two natural 
treatments indicate that there should be a safe mechanism to deliver oral or intravenous 
inhibitors of NEDD9 that can function without causing harmful amounts of cellular damage 
to healthy tissue. 
The scope of this dissertation on the role of NEDD9 in Cr(VI)-transformed cells was 
not exhaustive but rather focused. The study focused on the mechanism of action for how 
NEDD9 is involved in migration, invasion, and angiogenesis. NEDD9 can also have effects 
on cell survival, proliferation, and possibly other aspects of cancer progression that we did 
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not delve into. Migration, invasion, and angiogenesis are critical for highly aggressive and 
invasive tumor types. There are several checkpoints that a cell needs to overcome before 
in can become fully metastatic. Once the cancer cell has developed a resistance to apoptosis 
and self-renewal capability, the cell enters into the circulatory system and spreads to distant 
tissues. In order for this to occur the cell must be effective at remodeling its surrounding 
extracellular matrix. Then the cell must migrate through the stroma and pass into either the 
blood system or the lymphatic system. When the cancer cell can survive the journey 
through circulation, it must have the ability to invade new tissues i.e. bone, liver, brain etc. 
The goal is to inhibit signaling molecules involved in these cancer cell checkpoints. There 
may be opportunities to combine the current standard of care with a drug targeting NEDD9 
to further impede cancer cells from migration, invasion, and angiogenesis. 
There is reason to believe that NEDD9 may have a much broader impact and 
therefore be even more important as a therapeutic target because NEDD9 has been 
implicated as an upstream factor in multiple signaling pathways. The other two major 
pathways NEDD9 is involved in are apoptosis and cell cycle progression. NEDD9 is a 
protagonist during apoptosis. The protein is cleaved specifically by caspase at the DLVD 
and DDYD cleavage sites. These figments negatively regulate NEDD9 expression and 
mediate induction of apoptosis [136]. Cells that have developed apoptotic resistance are 
normally accompanied by much higher levels of NEDD9 without succumbing to apoptosis. 
In cell cycle progression NEDD9 aids in spindle formation, and when NEDD9 levels are 
too low cells can get stuck in G1 phase. This arrest leads to apoptosis if the problem is not 
resolved. Inhibiting NEDD9 by it’s shRNA did not lead to cell death in Cr(VI)-transformed 
cells as they already have resistance to apoptosis. Neither did the inhibition of NEDD9 
slow the cell growth and division rates in Cr(VI)-transformed cells. There may be a 
threshold level of NEDD9 that was still present in the cells after shRNA knockdown. 
Additionally, when normal BEAS-2B cells were treated with apigenin or α-pinene the 
subsequent reduction of NEDD9 did not cause cell death or arrest in G1 phase. 
The exact cause of NEDD9 overexpression is yet to be determined. One possible 
pathway would be that ROS induced SMAD2/3 alteration and the reduced capacity for 
Smurf1 and Smurf2 which are SMAD family HECT-type E3 ubiquitin ligases are directly 
involved with NEDD9 overexpression. These two ligases are downregulated in Cr(VI)- 
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transformed cells and inhibition of these SMAD family E3 ubiquitin ligases in normal 
BEAS-2B cells increased the expression of NEDD9. This provides a link between Cr(VI) 
exposure and the overexpression of NEDD9. Cr(VI) exposure also led to the over 
expression of NEDD9 mRNA. These two mechanisms are likely the major reasons why 
NEDD9 is overexpressed in Cr(VI)-transformed BEAS-2B cells. 
These Cr(VI)-transformed cells exhibited increased migration and invasion. Though 
the pathway for migration and invasion has been greatly illuminated, there are still 
additional questions that may be examined for understanding the whole picture. We found 
that NEDD9 was critical for Src activation and that there is direct binding with 
NEDD9/FAK and NEDD9/Src. Furthermore, the inhibition of NEDD9 by its shRNA 
obliterated binding between FAK and Src. This evidence suggests that NEDD9 is a critical 
mediator in this interaction having downstream effects in cellular adhesion, migration, and 
invasion. The interaction of FAK and Src is important for basal laminal adhesion, integrin 
signaling, and migration signaling. Interestingly, in normal cellular conditions FAK is 
auto-phosphorylated at Y397 as a precursor for Src binding, but in Cr(VI)-transformed 
cells this phosphorylation was not observed. This would be an interesting and enlightening 
future direction of study. It is possible that NEDD9 acts as a mediator to induce binding 
between FAK and Src without the phosphorylation of FAK at Y397 by binding directly to 
both kinases. 
The interaction of FAK and Src mediated my NEDD9 may have more than one 
downstream effect for tumor aggressiveness. First of all, we discovered the migration and 
invasion effects through the in vitro assays. The literature also suggests that FAK/Src 
interactions may play a critical role in angiogenesis. It is true that the cellular mechanisms 
for migration, invasion and angiogenesis overlap in many cases. The signaling cascades 
initiated from overexpression of NEDD9 may be one of these cases of overlap. FAK/Src 
has been reported to mediate angiogenesis by activating small GTPase RhoA and 
subsequently ROCK1 and ROCK2. In addition, DOCK180, Nck2, and Cdc42 were 
downstream targets of FAK/Src interaction [55-58]. This would seem to indicate that 
NEDD9 may mediate angiogenesis through multiple pathways. 
NEDD9 plays a critical role in active β-Catenin and E-Cadherin signaling. We found 
that NEDD9 can regulate active β-Catenin in Cr(VI)-transformed cells via reducing the 
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kinase activity of glycogen synthase kinase (GSK-3). GSK-3 is the primary kinase in the 
initiation of β-Catenin degradation. β-Catenin is sequestered by its destruction complex 
comprised of adenomatous polyposis coli (APC), Axin, casein kinase 1 (CK1), protein 
phosphatase 2A (PP2A), and GSK-3. GSK-3 phosphorylates β-Catenin which signals for 
the recruitment of an E3 ubiquitin ligase β-transducin repeats-containing protein (β-TrCP). 
This ubiquitination marks the end of β-Catenin as it is swiftly targeted for proteasomal 
degradation. In Cr(VI)-transformed cells active β-Catenin is highly expressed and the 
inhibition of NEDD9 increased GSK-3 kinase activity while reducing the active non- 
phosphorylated form of β-Catenin. 
In some cancers β-Catenin acts as a TCF/LEF transcription factor in the EMT 
process, however in Cr(VI)-transformed cells the downstream targets of TCF/LEF were 
not increased. Neither was the TCF/LEF more active as measured by a luciferase assay. It 
is known that β-Catenin is often associated with E-Cadherin as part of normal noncancer 
adhesion. In some situations, β-Catenin is glycosylated by DPAGT1 which then localizes 
CTHRC1 to the leading edge for wound healing and migration. In Cr(VI)-transformed cells 
it is likely that this mechanism is in play because of the highly elevated and active β- 
Catenin in combination with the lack of TCF/LEF gene transcription. 
Interestingly, VEGF can also stimulate β-Catenin to increase tumor aggressiveness. 
The VEGF-R promotes FAK activation and localized to cell junctions. VE-Cadherin and 
β-Catenin are dissociated from each other as part of cytoskeletal rearrangement. This has 
implications for the function of NEDD9. It would seem that NEDD9 then can doubly 
regulate FAK. First, NEDD9 can bind directly with FAK and assist with the FAK/Src 
complex formation. Second, by changing the transcriptional activity of HIF-1α, the 
expression and release of VEGF is altered. When NEDD9 is high there is a high expression 
of VEGF causing downstream FAK activation and cytoskeletal remodeling. 
Some studies suggested the NEDD9 expression can be altered downstream of 
FAK/Src complex. In Cr(VI)-transformed cells NEDD9 was able to regulate the formation 
of this complex by direct binding. However, when Src was inhibited there was no 
significant change to NEDD9 expression. This suggests that in Cr(VI)-transformed cells, 
NEDD9 is acting upstream and regulating the formation of this complex. This has 
implications in migration and invasion as shown in chapter 2 and in angiogenesis as shown 
65  
in chapter 3. Though these two pathways can be studied separately it is more likely that the 
pathways are intertwined as part of a total cellular shift in Cr(VI)-transformed cells. 
There are a number of interesting future directions that come from these studies of 
NEDD9. One future direction would be to look at NEDD9’s potential role in proliferation. 
Although knocking down NEDD9 in Cr(VI)-transformed cells had a negligible effect on 
proliferation, the overexpression of NEDD9 in BEAS-2B cells was not examined. There is 
reason to believe that NEDD9 may regulate Ras/MAPK pathways through VEGF or 
through Src and could increase cellular proliferation. Specifically, it would be interesting 
to examine ERK1/ERK2 as a downstream target of NEDD9. Additionally, NEDD9 
mediates the cell cycle with increased expression during S phase and association with the 
mitotic spindle. NEDD9 is directly associated with the Aurora A kinase at the centrosome 
at G2/M phase transition. This is needed for timing and control of mitosis [80]. An 
overexpression of NEDD9 may prove to be critical in enhanced proliferation of early 
cancer cell transformation. 
Genomic stability is an interesting application for further study of NEDD9. Since 
NEDD9 binds to Aurora A and can mediate cyclinB/Cdk1, the overexpression of NEDD9 
may cause changes in mitotic spindle formation rushing the process and generating 
genomic instability. This could be one of driving factors in early transformation of cells 
treating with Cr(VI). It may also be a mechanism for transformed cells to evade growth 
suppression signals. 
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CONTRIBUTION TO SCIENCE
1. My MPH work focused on mesothelioma survival disparities between Appalachian 
and Non-Appalachian Kentucky. The Appalachian region of Kentucky is known as 
one of the lowest socioeconomic regions in the United States having 38 distressed 
counties. Smoking rates in Appalachian Kentucky are also much higher than the rates 
throughout the rest of Kentucky. This study reported that mesothelioma survival was 
greatly reduced in patients who smoke. However, socioeconomic status had little 
effect on mesothelioma survival. This work contributes to the understanding of 
socioeconomic status in Appalachian Kentucky by illustrating little effect on 
mesothelioma survival.
a. Van Wie, P.G. (2017). A population-based survival analysis of mesothelioma 
and smoking in Appalachian and Non-Appalachian Kentucky. Theses and 
Dissertations-Public Health (M.P.H. & Dr.P.H.). 159.
http://uknowledge.uky.edu/cph_etds/159/
2. Hexavalent chromium (Cr(VI)) is a known human carcinogen. Our previous studies 
have demonstrated that chronic low dose Cr(VI) exposure leads to bronchial epithelial 
(BEAS-2B) cell transformation. Neural precursor cell expressed developmentally 
down-regulated protein 9 (NEDD9) is a key regulator in cancer progression involved 
in several different hallmarks of cancer including migration, invasion, and 
angiogenesis. This body of work aims to discover the mechanism of NEDD9 cell 
transformation and aggressiveness. It also aims to inhibit NEDD9 activity by treating 
with natural compounds.
a. Dai, J., Van Wie, P.G., Yenwong Fai, L., Kim, D., Wang, L., Poyil, P., Luo, J., 
Zhang, Z. (2016). Downregulation of NEDD9 by apigenin suppresses 
migration, invasion, and metastasis of colorectal cancer cells. Toxicology and 
Applied Pharmacology. Volume 311, 15 November 2016, Pages 106-112
b. Van Wie, P.G. (2017). Positive role of NEDD9 in migration, invasion, and 
angiogenesis of malignant transformed cells induced by chronic exposure to 
hexavalent chromium. Annual Meeting of Society of Toxicology. Baltimore,
MD.
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c. Van Wie, P.G. Kim, D., Zhang, Z. (2019). NEDD9 regulates metastasis of
Cr(VI)-transformed cells through FAK/Src and E-Cadherin/β-Catenin/Wnt
signaling pathways. toxicology and applied pharmacology pending.
d. Van Wie, P.G. Zhang, Z. (2019). Angiogenesis is increased in Cr(VI)-
transformed cells by increased HIF-1α translocation and transcriptional
activity mediated by NEDD9. Toxicology and applied pharmacology pending.
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Ongoing Research Support 
a. Major Advisor: Zhuo Zhang, University of Kentucky, College of Medicine
b. Course Work: Toxicology Seminar every semester, Biomolecules and
Metabolites, Molecular Biology and Genetics, Practical Statistics, Critical
Scientific Readings, Ethics in Scientific Research, Cell Biology and Signaling,
Physiological Communication, Research in Toxicology, Special Topics in IBS,
Drug Metabolism and Disposition, Environmental and Regulatory Toxicology,
Environmental Health, Cancer Epidemiology, Molecular Toxicology and
Carcinogenesis, Special Problems in Toxicology, Biology and Therapy of Cancer,
and Dissertation Residency.
c. Cumulative GPA: 3.40
d. Qualifying Examination: 11/09/2016
e. Presentations:
a. NEDD9 is critically involved in the migration of bronchial epithelial cells
exposed to hexavalent chromium via the Akt signaling pathway.
Presented at the new student orientation for Integrated Biomedical
Science College of Medicine. 2016. Lexington, KY.
b. Positive role of NEDD9 in migration, invasion, and angiogenesis of
malignant transformed cells induced by chronic exposure to hexavalent
chromium. Presented at the 56th Annual Meeting of Society of Toxicology.
2017, Baltimore, MD.
c. NEDD9 positively regulates cancer aggressiveness by mediating invasion
and angiogenesis in Chromium VI transformed bronchial epithelial cells.
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Presented Seminar to the University of Kentucky College of Medicine. 
2019, Lexington, KY. 
f. Career Development Activities: Ethics in Scientific Research, 
Completed Research Support 
OH007547, NIOSH Mannino, D. (PI) 01/01/13-05/01/14 
The Southeast Center for Agricultural Health and Injury Prevention at the University of 
Kentucky. 
The mission of the Southeast Center for Agricultural Health and Injury Prevention 
(SCAHIP) is to develop and sustain an innovative program of research, education, and 
health promotion to prevent work-related illness and injury and to improve the health of 
agriculture/forestry/fishing industry workers and their families in the southeastern United 
States. The Southeast Center conducts and supports applied research throughout its 10- 
state service region: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, 
South Carolina, Tennessee, Virginia, and West Virginia. 
